A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, 
and Immunogenicity of Chimpanzee Adenovirus Type 3- vectored Zaire 
ebolavirus  (ChAd3 -EBO- Z) and Modified Vaccinia Ankara- vectored 
Multivalent Filovirus ( MVA -BN® -Filo ) Vaccine Candidates 
DMID Protocol Number: 14-0092  
DMID Funding Mechanism: HHSN272201300016I  
Pharmaceutical Support Provided by: Bavarian Nordic A/S, GlaxoSmithKline , 
Janssen Vaccines & Prevention B.V.  
IND Sponsor: Division of Microbiology and Infectious Diseases (DMID), National 
Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health 
(NIH)  
Principal Investigator  (PI): Paul Spearman, MD  
DMID Clinical Project Manager : Cathy Cai , MS, BSN, RN  
DMID Scientific Lead: Hilary Marston, MD , MPH  
DMID Medical Officer:  Kay M. Tomashek , MD, MPH  
DMID Medical Monitor: Venus Shahamatdar , MD  
Draft or Version Number: 6.0 
Day Month Year 
30  January  2019  
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           2 
CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
The study trial  will be carried out in accordance with Good Clinical Practice (GCP) and as 
required by the following: 
• United States Code of Federal Regulations (CFR) 45 CFR Part 46 : Protection of Human 
Subjects 
• Food and Drug Administration (FDA) Regulations, as applicabl e: 21 CFR Part 50 (Protection 
of Human Subjects), 21 CFR Part 54 (Financial Disclosure by Clinical Investigators), 21 
CFR Part 56  (Institutional Review Boards), 21 CFR Part 11, and 21 CFR Part 312 
(Investigational New Drug Application  [NDA] ), 21 CFR 812 (Investigational Device 
Exemptions [IDE]) 
• International Conference on Harmonis ation : Good Clinical Practice ( ICH E6 ); 62 Federal 
Register 25691 (1997); and future revisions 
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research, Research Involving Human Subjects, as applicable  
• National Institu te of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , as 
applicable 
• Applicable Federal, State, and Local Regulations and Guidance 
  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           3 
CONFIDENTIAL  
 SIGNATURE PAGE  
The signature below provides the necessary assurance that this trial will be conducted according 
to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and 
ICH E6 Good Clinical Practice (GCP) guidelines. 
I agree to conduct the study in compliance with GCP and applicable regulatory requirements. 
I agree to conduct the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and Institutional Review Board (IRB)/ Independent or Institutional Ethics Committee ( IEC) approval, except when necessary to 
protect the safety, rights, or welfare of subjects.  
Site Investigat or Signature : 
Signed :  Date :  
 Name  
Title    
  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           4 
CONFIDENTIAL  
 TABLE OF CONTENTS  
STATEMENT OF COMPLIANCE  .................................................................................................2  
SIGNATURE PAGE  .......................................................................................................................3  
TABLE OF CONTENTS  .................................................................................................................4  
LIST OF TABLES  ...........................................................................................................................9  
LIST OF FIGURES  .......................................................................................................................10  
LIST OF ABBREVIATIONS  ........................................................................................................11  
PROTOCOL SUMMARY  .............................................................................................................14  
1 KEY ROLES  ..............................................................................................................20  
2 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ...................24  
2.1. Background Information .............................................................................................24  
2.1.1  Public Readiness and Emergency Preparedness  .........................................................25  
2.2. Rationale .....................................................................................................................26  
2.3. Potential Risks and Benefits  .......................................................................................29  
2.3.1.  Potential Risks ............................................................................................................29  
2.3.2.  Known Potential Benefits ...........................................................................................36  
3 OBJECTIVES AND OUTCOME MEASURES  ........................................................37  
3.1. Study Objectives .........................................................................................................37  
3.1.1.  Primary  .......................................................................................................................37  
3.1.2.  Secondary ...................................................................................................................37  
3.1.3.  Exploratory (if applicable)  ..........................................................................................37  
3.2. Study Outcome Measures ...........................................................................................37  
3.2.1.  Primary  .......................................................................................................................37  
3.2.2.  Secondary ...................................................................................................................38  
3.2.3.  Exploratory  .................................................................................................................38  
4 STUDY DESIGN  .......................................................................................................40  
5 STUDY ENROLLMENT AND WITHDRAWAL  ....................................................42  
5.1. Subject Inclusion Criteria  ...........................................................................................42  
5.2. Subject Exclusion Criteria ..........................................................................................44  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           5 
CONFIDENTIAL  
 5.3. Eligibility Criteria for Dose 2  .....................................................................................47  
5.4. Treatment Assignment Procedures  .............................................................................47  
5.4.1.  Randomization Procedures .........................................................................................47  
5.4.2.  Masking Procedures ....................................................................................................48  
5.4.3.  Discontinuation of Study Product ...............................................................................48  
5.4.4.  Study Withdrawal .......................................................................................................50  
5.4.5.  Handling of Withdrawals  ............................................................................................51  
5.4.6.  Termination of Study  ..................................................................................................51  
6 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  ...............................52  
6.1. Study Product Description ..........................................................................................52  
6.1.1.  Acquisition ..................................................................................................................52  
6.1.2.  Formulation, Packaging, and Labeling .......................................................................53  
6.1.3.  Product Storage and Stability .....................................................................................53  
6.2. Dosage, Preparation and Administration of Study Intervention/ 
Investigational Product ...............................................................................................54  
6.3. Modification of Study Intervention/Investigational Product for a Subject ................56  
6.4. Accountability Procedures for the Study Intervention/Investigational Product(s) ....................................................................................................................56
 
6.5. Assessment of Subject Compliance with Investigational Product  .............................56  
6.6. Concomitant Medications/Treatments ........................................................................56  
7 STUDY SCHEDULE  .................................................................................................58  
7.1. Screening  ....................................................................................................................58  
7.2. Enrollment/Baseline  ...................................................................................................59  
7.3. Follow-up ....................................................................................................................60  
7.3.1.  Follow- up Visits, post first vaccination  ......................................................................60  
7.3.2.  Follow- up Vaccination Visit  .......................................................................................61  
7.3.3.  Follow- up Visits, post second vaccination  .................................................................63  
7.3.4.  Follow-up Phone Calls ...............................................................................................63  
7.4. Final Study Visit  .........................................................................................................64  
7.5. Early Termination Visit (if needed)  ............................................................................64  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           6 
CONFIDENTIAL  
 7.6. Unscheduled Visit (if needed) ....................................................................................65  
8 STUDY PROCEDURES/EVALUATIONS  ...............................................................66  
8.1. Clinical Evaluations  ....................................................................................................66  
8.2. Laboratory Evaluations  ...............................................................................................67  
8.2.1.  Clinical Laboratory Evaluations  .................................................................................67  
8.2.2.  Special Assays or Procedures  .....................................................................................68  
8.2.3.  Specimen Preparation, Handling, and Shipping .........................................................70  
9 ASSESSMENT OF SAFETY  .....................................................................................71  
9.1. Specification of Safety Parameters  .............................................................................71  
9.2. Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ...................................................................................................................71  
9.2.1.  Adverse Events ...........................................................................................................71  
9.2.2.  Reactogenicity  ............................................................................................................73  
9.2.3.  Serious Adverse Events  ..............................................................................................77  
9.2.4.  Procedures to be Followed in the Event of Abnormal Laboratory Test Values or Abnormal Clinical Findings ...................................................................................77
 
9.3. Reporting Procedures ..................................................................................................78  
9.3.1.  Serious Adverse Events  ..............................................................................................78  
9.3.2.  Regulatory Reporting for Studies Conducted Under DMID-Sponsored IND ............79  
9.3.3.  Other Adverse Events .................................................................................................79  
9.3.4.  Reporting of Pregnancy ..............................................................................................80  
9.4. Type and Duration of Follow- up of Subjects after Adverse Events  ...........................80  
9.5. Halting Rules ..............................................................................................................80  
9.6. Safet y Oversight (ISM plus SMC) .............................................................................81  
9.6.1.  Independent Safety Monitor (ISM) ............................................................................81  
9.6.2.  Safety Monitoring Committee (SMC) ........................................................................82  
10 CLINICAL MONITORING  .......................................................................................84  
10.1.  Site Monitoring Plan ...................................................................................................84  
11 STATISTICAL CONSIDERATIONS .......................................................................85  
11.1.  Study Hypotheses .......................................................................................................85  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           7 
CONFIDENTIAL  
 11.2.  Sample Size Considerations .......................................................................................85  
11.3.  Planned Interim Analyses  ...........................................................................................85  
11.3.1.  Interim Safety Review  ................................................................................................85  
11.3.2.  Interim Immunogenicity Review  ................................................................................85  
11.4.  Final Analysis Plan  .....................................................................................................86  
11.4.1.  Analysis Populations ..................................................................................................86  
11.4.2.  Safety Data  ..................................................................................................................87  
11.4.3.  Secondary Immunogenicity Data ...............................................................................87  
11.4.4.  Exploratory Data Analyses  .........................................................................................88  
11.4.5.  Missing Values and Outliers  .......................................................................................89  
12 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  ...............................................................................................91  
13 QUALITY CONTROL AND QUALITY ASSURANCE  .........................................92  
14 ETHICS/PROTECTION OF HUMAN SUBJECTS ..................................................93  
14.1.  Ethical Standard  ..........................................................................................................93  
14.2.  Institutional Review Board  .........................................................................................93  
14.3.  Informed Consent Process ..........................................................................................93  
14.3.1.  Informed Consent/Assent Process (in Case of a Minor)  ............................................95  
14.4.  Exclusion of Women, Minorities, and Children (Special Populations) ......................95  
14.5.  Subject Confidentiality  ...............................................................................................96  
14.6.  Study Discontinuation ................................................................................................97  
14.7.  Costs, Subject Compensation, and Research Related Injuries ...................................97  
14.8.  Future Use of Stored Specimens and Data .................................................................97  
15 DATA HANDLING AND RECORD KEEPING ......................................................99  
15.1.  Data Management Responsibilities  ............................................................................99  
15.2.  Data Capture Methods  ................................................................................................99  
15.3.  Types of Data ..............................................................................................................99  
15.4.  Timing/Reports  ...........................................................................................................99  
15.5.  Study Records Retention ..........................................................................................100  
15.6.  Protocol Deviations ..................................................................................................100  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           8 
CONFIDENTIAL  
 16 PUBLICATION POLICY ........................................................................................101  
17 LITERATURE REFERENCES  ................................................................................102  
18 SUPPLEMENTS/APPENDICES  .............................................................................105  
APPENDIX A: SCHEDULE OF STUDY PROCEDURES AND EVALUATIONS .................106  
APPENDIX B: ESTIMATED COMPARATIVE DAILY DOSES - INHALED 
CORTICOSTEROIDS FOR LONG- TERM ASTHMA CONTROL (12 
YEARS AND OLDER)  ............................................................................................109  
APPENDIX C: ACCEPTABLE RANGES OF SCREENING LABORATORY 
MEASUREMENTS  ..................................................................................................111  
  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           9 
CONFIDENTIAL  
 LIST OF TABLES  
Table 1: Treatment Arms  ...............................................................................................................40  
Table 2: Blood Volumes (ml)  ........................................................................................................69  
Table 3:  Local (Injection Site) Reactogenicity Grading  ...............................................................73  
Table 4: Local (Injection Site) Reactogenicity Measurements  ......................................................74  
Table 5: Subjective Systemic Reactogen icity Grading  ..................................................................74  
Table 6: Quantitative Systemic Reactogenicity Grading  ...............................................................75  
Table 7:  Blood Pressure and Pulse Grading .................................................................................75  
Table 8: Clinical Safety Laboratory Adverse Event Grading (Hematology) ................................76 
Table 9: Clinical Safety Laboratory Adverse Event Grading (Chemistry)  ....................................76 
 
  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           10 
CONFIDENTIAL  
 LIST OF FIGURES  
Figure 1: Schematic of Study Design ............................................................................................19  
  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           11 
CONFIDENTIAL  
 LIST OF ABBREVIATIONS  
 
Ad Adenovirus  
ADCC  Antibody -Dependent Cell -Mediated Cytotoxicity  
AE Adverse Event/Adverse Experience  
ALT  Alanine Transaminase  
ANC  Absolute Neutrophil Count  
β-HCG  Beta-human chorionic gonadotropin  
BMI  Body Mass Index  
BP  Blood Pressure  
Bpm  Beats per Minute  
BUN  Blood Urea Nitrogen  
CMS  Clinical Materials Services  
CFR  Code of Federal Regulations  
ChAd3  Chimpanzee adenovirus Type 3  
CONSORT  Consolidated Standards of Reporting Trials  
CRF  Case Report Form  
CSR  Clinical Study Report  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH, DHHS  
EBOV  Zaire  ebolavirus  
eCRF  Electronic Case Report Form  
FDA  Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act  
FWA  Federal Wide Assurance  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           12 
CONFIDENTIAL  
 GCP  Good Clinical Practice  
HBsAg  Hepatitis B Surface Antigen  
HCV  Hepatitis C  
Hgb Hemoglobin  
HgbA1C  Hemoglobin A1C  
HIV Human Immunodeficiency Virus  
HRSA  Health Resources  and Services Administration  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IEC Independent or Institutional Ethics Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
IU Infectious Units  
MedDRA Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
N Number (typically refers to subjects)  
NDA  New Drug Application  
NEJM  New England Journal of Medicine  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, DHHS  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
PHI Protected Health Information  
PI Principal Investigator  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           13 
CONFIDENTIAL  
 PK Pharmacokinetics  
PT Prothrombin Time  
PTT Partial thromboplastin Time  
PU Particle Unit s 
QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event/Serious Adverse Experience  
SMC  Safety Monitoring Committee  
SOP Standard Operating Procedure  
US United States  
V Visit  
WBC  White Blood Cell  
WHO  World Health Organization  
 
   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           14 
CONFIDENTIAL  
 PROTOCOL SUMMARY 
 
Title:  A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, 
and Immunogenicity of Chimpanzee Adenovirus Type 3- vectored 
Zaire ebolavirus  (ChAd3-EBO-Z) and Modified Vaccinia Ankara- 
vectored Multivalent Filovirus (MVA -BN®-Filo) Vaccine Candidates  
Phase:  1 
Population:  60 evaluable males and non -pregnant females, 18 -45 years old, 
inclusive, who are in good health and meet all eligibility criteria  
Number of Sites:  1 
Study Duration:  Approximately 15 months  
Subject Participation 
Duration : Approximately 6 months  
Description of Agent or 
Intervention:  Zaire  ebolavirus  (ChAd3 -EBO -Z) vaccine, consisting of a 
recombinant, replication-defective chimpanzee adenovirus (Ad) type 3  
(ChAd3) -derived vector expressing the Zaire ebolavirus  glycoprotein 
(GP), will be administered by intramuscular (IM) injection in a single 
dose of 2 x 1011 vp  virus particles) on Day 1. Booster vaccination will 
take place on Day 8 for all groups (group 1: placebo, group 2: ChAd 3-
EBO-Z at dose of 2 x 1011 vp {homologous }, group 3: replication 
defective MVA -BN®-Filo 1 x 108 Infectious Units ( IU) per dose  
vaccine {heterologous}  delivered by IM injection). The placebo will 
be normal saline (0.9% Sodium Chloride, USP). 
Objectives : 
 Primary:  
• Assess the safety and reactogenicity of study product s by study 
group when administered IM to healthy adults . 
Secondary : 
• Assess the antibody response to Zaire ebolavirus (EBOV) 
glycoprotein ( GP) by study group.  
 
Exploratory:  
• Assess the EBOV neutralizing antibody titers by study group.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           15 
CONFIDENTIAL  
 • Assess antibody functionality by antibody -dependent cell -
mediated cytotoxicity (ADCC) responses by study group.  
• Assess activation of CD4+ and CD8+ T cells in multiple cell 
subpopulations by study group.  
• Assess inflammation via cytokine secretion and C-reactive protein 
(CRP) by study group.  
• Assess EBOV GP -specific T cell responses by study group.  
• Assess ChAd3 -specific T cell responses by study group.  
• Assess plasmablast frequencies by study group.  
• Assess B -cell receptor (BCR) repertoire by study group.  
• Assess and characterize change in gene expression in PBMCs by 
study group.  
• Identify gene expression changes associated with adaptive humoral 
and/or cellular immune responses.  
Outcome Measures:  
 
 
 
 
 
 
 Primary:  
• Frequency and severity of solicited local and systemic 
reactogenicity from the time of study vaccine administration 
through 7 days post-vaccination.  
• Frequency and severity of vaccine -related unsolicited adverse 
events (AEs) from the first study vaccination through 28 days post second vaccination.  
• Frequency and severity of clinical safety laboratory AEs from the 
time of first study vac cination through approximately 28 days after 
the second vaccination.  
• Frequency of Serious Adverse Events (SAEs) and vaccine-related Medically Attended Adverse Events (MAAEs) through 6 months 
post first vaccination.  
Secondary:  
• Seroconversion defined as ant i-EBOV GP ELISA titer > 50 if 
baseline (Day 1) titer ≤ 50 or fold rise > 4 as compared to baseline 
if baseline titer > 50 on Day 8, 15, 22, 29 and 36.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           16 
CONFIDENTIAL  
 • Geometric mean titer (GMT) on Day 1, 8, 15, 22, 29 and 36 as 
measured by anti -EBOV GP ELISA.  
• Geometric mean fold rise (GMFR) in titer on Day 8, 15, 22, 29 
and 36 compared to baseline (Day 1) as measured by anti -EBOV 
GP ELISA.   
Exploratory:  
• GMT of neutralizing antibodies to EBOV GP at Day 1, 8 and 15 as 
measured by EBOV GP pseudovirion neutralization assay.  
• GMFR in titer on Day 8 and 15 compared to baseline (Day 1) as 
measured by EBOV GP pseudovirion neutralization assay.  
• Change in the percent age of killed cells as measured by ADCC on 
Day 8, 15, 22, 29, and 36 compared to baseline (Day 1).  
• Change in percentage of activated CD4+ and CD8+ T cells for each cell subpopulation on Day 8 and 15 compared to baseline 
(Day 1) as measured by flow cytometry.  
• Change  in cytokine concentration and CRP on Day 2, 3, 4, 6, 8, 9 
and 15 compared to baseline (Day 1) as measured by Luminex assay and clinical laboratory CRP assay, respectively.  
• Change in percentage of EBOV GP -specific cytokine secreting 
CD4+ and CD8+ T cells on Day 8, 15, 22, and 36 compared to 
baseline (Day 1) as measured by intracellular cytokine staining 
(ICS).  
• Change in percentage of EBOV GP -specific CD4+ and CD8+ T 
cells on Day 8  and 15 as compared to baseline (Day 1) measured 
by tetramer staining for predominant human leukocyte antigen 
(HLA) types.   
• Change in percentage of ChAd3-specific cytokine secreting CD4+ 
and CD8+ T cells on Day 8, 15, 22 and 36 compared to baseline 
(Day 1) as measured by ICS.  
• Change in percentage of CD19+CD27+CD38+ plasmablasts on 
Day 8 and 15 compared to baseline (Day 1) as measured by flow cytometry.   
• Change in B -cell repertoire (BCR) on Day 8 and 15 as compared 
to baseline (Day 1) from sorted CD19+ CD27+ CD38+ 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           17 
CONFIDENTIAL  
 plasmablasts as measured by immunoglobulin heavy chain 
sequencing.   
• Characterization of antigen -specific BCR as measured by yeast 
display on day 36.  
• Change in gene expression in PBMCs on Day 2, 3, 4, 6, 8, 9, and 
15 compared to baseline (Day 1) as measured by RNA-Seq.   
• Identification of gene expression changes on Day 2, 3, 4, 6, 8, 9, 
and 15 associated with each subject’s peak change in percentage of 
EBOV GP -specific cytokine secreting CD4+ and CD8+ T cells 
across Day 15, 22, and 36.  
• Identification of gene expression changes on Day 2, 3, 4, 6, 8, 9, and 15 associated with each subject’s peak anti-EBOV GP ELISA 
titer across Day 15, 22, 29, and 36.  
• Identification of gene expression changes on Day 2, 3, 4, 6, 8, 9, 
and 15 associated with each subject’s EBOV neutralizing antibody 
titer at Day 15.  
•  Identification of gene expression changes on Day 2, 3, 4, 6, 8, 9, 
and 15 associated with each subject’s peak percent age of killed 
cells as measured by ADCC across Day 15, 22, 29, and 36.  
Description of Study Design:  This is a Phase 1, randomized, double -blind trial of 60 evaluable males 
and non- pregnant females, 18 -45 years old, inclusive, who are in good 
health , meet all eligibility criteria , and do not meet any exclusion 
criteria . This trial is designed to assess the safety, reactogenicity and 
immunogenicity of a  chimpanzee adenovirus vector expressing  Zaire 
ebolavirus  glycoprotein (ChAd3-EBO-Z) vaccine with or without 
MVA- BN®- Filo boost for the prevention of Ebola  virus disease. 
ChAd3-EBO-Z will be administered intramuscularly on Day 1 
followed by either  placebo (Group 1), ChAd3-EBO-Z (Group  2), or 
MVA- BN®- Filo (Group 3)  at Day 8.   
Potential subjects will be screened by history, physical exam, ECG, 
vital signs, height and weight, and clinical laboratory tests. A 
urinalysis will be done for urine protein and drug screening for opiates. 
Potential female subjects of childbearing potential will have a serum 
pregnancy test. In addition, potential subjects will be screened for 
Human Immunodeficiency Virus (HIV) type 1 & 2 antibody, Hepatitis 
C Virus (HCV) antibody, and Surface Antigen for Hepatitis B Virus 
(HBsAg) prior to enrollment.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           18 
CONFIDENTIAL  
 Subjects will be randomized in double -blind fashion per the schedule 
outlined in Section 4, Table 1 . 
Reactogenicity will be measured by the occurrence of solicited 
injection site and systemic AEs. Subjects will maintain a memory aid 
through 7 days post each vaccination, recording temperature, solicited 
local and systemic symptoms. Unsolicited non -serious adverse events 
(AEs) will be collected from the time of first study vaccinat ion through 
approximately 28 days after the second  study vaccination. Serious AEs 
(SAEs)  and MAAEs occurring from the time of the first study 
vaccination through approximately 6 months after the first study 
vaccination will be collected. Clinical safety labs will be collected on Day 1, 8, 15 , 29, and 36; if labs are abnormal, they will be assessed, 
documented, reported, and followed. until the lab returns to the 
subject’s baseline value or  has stabiliz ed. 
Immunogenicity testing will be performed as outlined in Section 
8.2.2.    
The duration of this trial for each subject will be approximately 6 
months.  
Estimated Time to Complete 
Enrollment:  Approximately 5 months  
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           19 
CONFIDENTIAL  
   
Figure  1: Schematic of Study Design  
 
 
 
  
Randomize 1:1:1  
Arm 1: 20 subjects  
ChAd3-EBO-Z  
+  Placebo  
Arm 3: 20 subjects  
ChAd3-EBO-Z  
+ MVA- BN® -Filo  
Arm 2: 20 subjects  
ChAd3-EBO-Z  
+  ChAd3 -EBO-Z  
Planned Enrollment:  Total N = 60 healthy subjects (males & non -pregnant females 18 -45, inclusive)  
Obtain informed consent. Screen subjects by criteria; obtain medical history.  
Perform urine pregnancy test; collect blood for assays;  
Administer Study Product/Inte rvention per subject assignment  
Follow -up for Safety, Reactogenicity and Immunogenicity  
Assessment of Final Study Outcome 
Measures  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           20 
CONFIDENTIAL  
 1 KEY ROLES  
Individuals:  
Site Principal Investigator:    
Paul Spearman, MD, MA  
Cincinnati Children’s Hospital Medical Center  
3333 Burnet Ave., MLC 6014  
Cincinnati, OH  45229-3039  
DMID Clinical Project 
Manager:  Shu Yi (Cathy) Cai, MS, BSN, MS  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
5601 Fishers Lane, Room 8E65  
Rockville, MD  20892-9825  
Work: 240-507 -9589  
Email: cais@niaid.nih.gov   
DMID Scientific Lead:  Hilary D. Marston, MD, MPH  
Office of the Director  
NIAID, NIH  
31 Center Drive, Room 7A05C  
Bethesda, MD  20892  
Work: 301-219-8709  
Email: hilary.marston@nih.gov  
DMID Medical Officer   
 
 
 
 
 Kay M. Tomashek, MD, MPH, DTM  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
5601 Fishers Lane, Room 7G11  
Rockville, MD  20892-9825  
Work: 240-669 -2880 (office) and 240-383 -0540 (mobile)  
Email: kay.tomashek@nih.gov  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           21 
CONFIDENTIAL  
 DMID Medical Monitor  Venus Shahamatdar, MD  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
5601 Fishers Lane, Room 7E54  
Rockville, MD  20892-9825  
Work: 240-627 -3369  
Email: venus.shahamatdar@nih.gov  
Institutions:  Cincinnati Children’s Hospital Medical Center  
3333 Burnet Ave., MLC 6014  
Cincinnati, OH  45229-3039  
Paul Spearman, MD, MA  
Work:  513-636 -4509  
Fax:  513- 636-7682  
e-mail: paul.spearman@cchmc.org  
Safety and 
Pharmacovigilance 
Contractor:  
 DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS) 
6500 Rock Spring Dr., Suite 650  
Bethesda, MD 2081 7 
SAE Hot Line: 1 -800-537 -9979 (US)  
SAE Fax: 800 -275- 7619 (US)  
SAE Email: PVG@dmidcroms .com   
Statistical and Data 
Coordinating Center  
(SDCC) : 
 The Emmes Corporation  
401 N. Washington St., Suite 700  
Rockville, MD 20850  
Phone: 301-251 -1161  
Email: virolog y@emmes.com   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           22 
CONFIDENTIAL  
 Study Agent Repository:  
 Fisher BioServices  
c/o DMID Clinical Materials Services (CMS) Contract  
20439 Seneca Meadows Parkway  
Germantown, MD 20876  
Phone: 240-477 -1350  
Fax: 240- 477-1360  
Email: DMID.CMS@ThermoFisher.com   
Local (Clinical) Laboratory : Cincinnati Children’s Hospital Medical Center  
CORE Laboratories  
3333 Burnet Ave., Building B, MLC 1010  
Cincinnati, OH  45229  
Pharmaceutical  
Representatives 
 Janssen Vaccines and Prevention BV  
Macaya Douoguih , MD, MPH  
Janssen Vaccines and Prevention BV 
Newtonweg 1  
Leiden 2333 CP  
Netherlands  
Email: MDouogui@its.jnj.com 
Phone: +31 71 519 7777  
 GSK Vaccines  
Robert A. van den Berg  
Translational Science Leader  
14200 Shady Grove Rd, Mail Stop RVK1000  
Rockville, Maryland 20850 
Email: Robert.x.van-den -Berg @GSK.com  
Phone:  202- 809-1128  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           23 
CONFIDENTIAL  
  Bavarian Nordic GmbH  
Dr. Heinz Weidenthaler  
Director Pharmacovigilance, QPPV  
Fraunhoferstrasse 13  
D-82152 Martinsried 
Germany  
Phone: +49 89255446457  
Mobile: +49 1728623292  
Email: Heinz.weidenthaler@bavarian -nordic.com   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           24 
CONFIDENTIAL  
 2 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
2.1. Background Information  
Ebola virus es are RNA viruses in the family Filoviridae. Ebola viruses have been associated with 
sporadic outbreaks characterized by severe hemorrhagic disease and high case fatality ratios. 
Zaire ebolavirus  (EBOV) and Sudan ebolavirus  (SUDV) were both identified in 1976 during 
two simultaneous outbreaks in Zaire (now Democratic Republic of the Congo) and Sudan, 
respectively1. Taï Forest ebolavirus  (TAFV) arose in C ôte d’Ivoire in 1994 and was noted to be 
distinct from both EBOV and SUDV2. Since 1994, outbreaks of Ebola virus disease (EVD) have 
occurred almost yearly, with the Democratic Republic of Congo being the most frequently 
affected. Bundibugyo ebola virus (BDBV) is the most recently described member of the genus, 
identified in Uganda in 20072. A fifth member of the genus, Reston ebolavirus , was described in 
1990 but is not known to cause human disease3. The natural reservoir of the related filovirus 
Marburg virus (MARV)  has been identified as the Egyptian fruit bat4,5. The natural reservoir for 
Ebola viruses is less certain, although fruit bats are likely involved in transmission events to non-human primates and to humans. After an incubation period ranging from 2-21 days, Ebola-associated EVD manifests initially with nonspecific symptoms such as fever, headaches, muscle 
pain, joint pain, general malaise and gastrointestinal symptoms and in a minority of cases involve 
hemorrhagic complications
6,7. One of the most concerning aspects of filovirus outbreaks in 
humans is the high mortality rate observed. Case fatality rates for EVD measured using World 
Health Organization (WHO) data prior to 2015 revealed on overall rate of 65.4%, which ranged 
by species from 76% for EBOV to 55% for SUDV and 37% for BDBV8. The case fatality rate 
tends to be highest in the earliest days of an outbreak due to reporting bias of severe cases. The 
availability of intensive medical support may also influence the outcome, since the case fatality 
rate was substantially lower among repatriated US and European patients during the 2014 
outbreak of EBOV9. While it may be postulated that the experimental clinical interventions that 
these patients received contributed to their outcomes , the same phenomenon was seen in 1967 in 
the Marburg outbreak10 where 31 patients were cared  for using only modern supportive care 
measures including dialysis; the case fatality rate was 22%.  
Development of therapeutics and of preventive vaccines against filoviruses is a high global public health priority. The importance of this effort was great ly magnified by the scope of the 
2014-2016 West African outbreak of EBOV. The outbreak began in Guinea with an index case of a 2- year-old child who died from EVD in December 2013
11. The outbreak subsequently 
became the largest EVD outbreak in history, involving predominantly Guinea, Sierra Leone, and Liberia. According to the WHO, this outbreak involved 28,610 cases and 11, 308 deaths (as of 
March 30 , 2016) . Importantly, healthcare worke rs were  disproportionally affected and this 
resulted in further challenges in the care of EVD patients. Imported cases in Western countries 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           25 
CONFIDENTIAL  
 stimulated additional attention to the epidemic and illustrated the potential for global impact 
beyond the affected areas in Africa. The extent of the epidemic and the lack of proven therapies 
and vaccines made further research on Ebola an urgent priority.  
Vaccines against Ebola viruses and MARV are under development by a number of academic 
investigators and manufacturers12,13. Developing a safe and effective vaccine against filoviruses 
is likely to require a greater understanding of the nature of protective immunity against these 
agents. Animal data support the  importance of antibody- mediated protection in studies with 
DNA prime -adenovirus boost, Ebola virus- like particles (VLPs), vesicular stomatitis virus 
(VSV) -based vaccines, and parainfluenza virus- based vaccines14. In contrast, a recombinant 
adenovirus serotype 5 (Ad5) EBOV vaccine protected macaques from infection primarily 
through the activity of CD8+ T cell responses15. Acute protection from EBOV in macaques was 
also elicited by a chimpanzee Ad3 vector EBOV vaccine, and protection correlated with 
antibody re sponses, while long- term protection in this study required functional CD8+ T cell 
responses and was enhanced with a modified vaccinia Ankara (MVA) boost16. Therefore, there is 
currently evidence supporting both antibody-mediated protection and cell-mediated protection 
against filoviruses. Our understanding of immune correlates of protection is limited largely to 
animal models, as the sporadic nature of Ebola outbreaks offers  limited opportunities for 
examining protection in humans. It is notable that in the intensely studied patients cared for at 
Emory University in 2014 the resolution of viremia correlated with the presence of activated CD8 T cells and this occurred prior to the presence of detectable IgG antibody response
17.  
2.1.1 Public Readiness and Emergency Preparedness 
This protocol, the ChAd3- EBO-Z vaccine manufactured by GSK and the MVA -BN® -Filo 
vaccine manufactured by Bavarian Nordic, are covered under the Public Readiness and Emergency Preparedness Act (PREP Act).  Under the PREP Act, covered persons are immune 
from liability action s brought from the administration or use of a covered countermeasure that is 
the subject of a declaration. The PREP Act provides immunity for covered persons (such as manufacturers, distributers, program planners and other qualified persons who prescribe, administer or dispense the study vaccine) from tort liability, unless the injury was caused by willful misconduct.  
The PREP Act also authorized a “Covered Countermeasures Process Fund” to provide compensation to eligible individuals who suffer specified in juries from administration or use of a 
countermeasure pursuant to the declaration. Any requests for compensation must be filed within one year of administration or use of the countermeasure.  Requests wo uld go to the HRSA 
(Health Resources and Services Admi nistration) Preparedness Countermeasures Injury 
Compensation Program ( http://www.hrsa.gov/cicp/ ). Compensation may then be available for 
medical benefits, lost wages and death benefits to eligible individuals for specified injuries in 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           26 
CONFIDENTIAL  
 accordance with regul ations published by the Secretary. Eligibility for compensation and the 
injuries for which compensation may be available are further defined by regulation. 
An individual who suffers a serious physical injury or death from administration and use of the 
study vaccine must first seek compensation from the Covered Countermeasures Process Fund.  A 
serious physical injury means an injury that is life threatening, results in, or requires medical or 
surgical intervention to prevent, permanent impairment of a body function or permanent damage 
to body structure. Any compensation will be reduced by public or private insurance or worker’s compensation available to the injured individual. 
If no funds have been appropriated to the compensation program, the Secretary does not make a 
final determination on the individual’s request within 240 days, or if the individual decides not to 
accept the compensation, the injured individual or his representative may pursue a tort claim in the United States District Court for the District of Columbia, but only if the claim involves willful misconduct, is pled with particularity required under the PREP Act, verified, and accompanied by an affidavit by a physician who did not treat the individual and certified medical 
records. Any award is reduced by any public or private insurance or worker’s compensation 
available to the injured individual. Awards for non-economic damages, such as pain, suffering, 
physical impairment, mental anguish, and loss of consortium are also limited. If the individu al 
accepts compensation, or if there is no willful misconduct, then the individual does not have a tort claim that can be filed in a United States Federal or a State court.  
2.2. Rationale  
Development of a vaccine to protect from  infection or disease caused by EBOV is a national 
priority. No licensed vaccine s or therapeutics are currently available for EVD . The extensive 
EBOV  outbreak in West Africa during 2014- 2016 illustrates the urgent need for preventive 
measures against Ebola. This P hase 1 vaccine  trial will provide a unique opportunity to 
define innate immune responses elicited by a promising chimpanzee adenovirus vector expressing Zaire  ebolavirus  glycoprotein (EBOV GP). This trial offers a chance to compare 
responses elicited by homologous vs. heterologous boosting using a rapid vaccination 
schedule. The study may also have applicability beyond Ebola as the vaccine vectors (ChAd 
and MVA) are being used to develop vaccines against other pathogens.  
The Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (VRC/ NIAID), National Institutes of Health (NIH) in the United States of America (US) has been developing replicati on-defective recombinant chimpanzee adenovirus Type3 -vectored 
monovalent and bivalent filovirus vaccine candidates. These include monovalent ChAd3 -
EBO -Z for EBOV  and ChAd3 -MARV for MARV , as well as bivalent ChAD3 -EBO  (EBOV  
+ SUDV ). ChAd3 recombinants were developed  using the Okairos adenovirus vaccine 
platform technology acquired by GlaxoSmithKline (GSK) in May 2013
18. The DNA 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           27 
CONFIDENTIAL  
 fragment inserted in ChAd3- EBO -Z encodes the wild -type (WT) glycoprotein (GP) from the 
species EBOV.  GP is expressed on the surface of the virus and is critical for attachment to 
host cells and catalysis of membrane fusion. GP is the major target for neutralizing antibody 
responses against Ebola viruses and contains cytotoxic T lymphocyt e and T helper epitopes 
that contribute to protection in animal models15,16.  
Pre-clinical immunogenicity and efficacy studies were conducted with the investigational 
ChAd3 -EBO -Z vaccine and with the investigational ChAd3- EBO (bivalent) vaccine in 
cynomolgus macaques. Overall, it was shown that a single intramuscular (IM) dose of 1x109 
or 1x1010pu of either monovalent or bivalent vaccine elicited anti -GP antibodies and antigen-
specific CD4+ and CD8+ T- cell responses. 100% of macaques receiving a single IM dose of 
1010 - 1011 pu of the bivalent ChAd3- EBO were protected from against EBOV or SUDV 
challenge 4- 5 weeks after vaccination, whereas a dose of 1x109 pu provided protection in 
half of the vaccinated cynomolgus macaques.  ChAd3 -EBO -Z given at 1010 or 1011 pu was 
100% protective against EBOV challenge at 4 -5 weeks post -vaccination.  Ten months after 
vaccination, the humoral and the cellular immune response had declined, and protection 
against EBOV  challenge was observed in half of the animals who had received a dose of 1011 
pu and in none of the animals who had received a dose of 1x1010 pu16. Durability of 
protection was extended to ten months in macaques receiving ChAd3 -EBO priming fol lowed 
by bivalent (EBOV, SUDV GP) MVA boosting16.   
Phase 1 and Phase 2 trials support the use of replication- defective adenovirus approaches to 
stimulate Ebola -specific immune responses in humans. VRC  205 evaluated two replication-
defective recombinant Ad5 vectors that encoded GP from the species EBOV and SUDV, 
respectively.  Antigen- specific humoral and cellular responses were observed following a  
single intramuscular injection  and the vaccine was generally safe and well -tolerated19. VRC 
207 evaluated bivalent ChAd3 -EBO in healthy adults. At 4 weeks after vaccination, vaccine -
induced antibodies to EBOV GP were present in 90% of individuals receiving 2 x 1010 pu 
dose and 100% of individuals receiving a 2 x 1011 pu dose.  GP-specific CD8 T cell responses 
were detected in 20% of individuals by week 4 in the lower dose group and 70% of individuals receiving the higher dose. Overall the study supported the safety and immunogenicity of a single dose of 
ChAd3 -EBO  in humans20. ChAd3 -EBO-Z is a monovalent 
vaccine that has also been evaluated in a series of trials (a total of 15 clinical trials enrolling 
approximately 5,000 subjects) in U.S. and international sites, either with or without MVA boost. In a phase 1 study performed in the United Kingdom , a single dose of ChAd3- EBO- Z was 
administered to 60 healthy adult volunteers. No significant safety concerns with ChAd3- EBO- Z 
were identified in this study. Boosting with MVA- BN® -Filo (described below) significantly 
enhanced GP-specific antibody and CD8+ T cell responses that were elicited by ChAd3- EBO- Z, 
and antibodies remained higher in the boosted subjects 6 months after vaccination
21. A phase 1 
trial performed in the United States and  in Mali during the West African Ebola epidemic also 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           28 
CONFIDENTIAL  
 evaluated ChAd3- EBO- Z prime and MVA - BN® -Filo boost. Safety was again demonstrated, 
and a 1 x 1011 pu dose of ChAd3- EBO -Z was identified as sufficiently immunogenic to move 
forward as a potential means o f interrupting transmission in the African setting. Boosting with 
MVA- BN® -Filo increased the magnitude and extended the duration of antibody responses and 
anamnestic polyfunctional CD4+ and CD8+ T cell responses22. A phase 2 trial performed in 
Liberia enrolled 500 adults who received a single dose of ChAd3- EBO- Z. Side effects were not 
severe, and anti -GP antibodies developed in 70% of participants by 1 month and remained 
detectable at 12 months in 63.5% of participants23.  
The MVA multi -filovirus vaccine from Bavarian Nordic (MVA- mBN226B , referred to 
subsequently as MVA- BN® -Filo) encodes the GPs of EBOV, SUDV, and MARV, together 
with the nucleoprotein (NP) of TAFV. Since GP is the surface glycoprotein, it is the natural 
target of neutralizing antibodies, which often (but not always) correlate with protection in animal models
24. The major targets of cellular immunity in humans are the NP followed by 
the GP protein17. Therefore , the potential with this va ccine is to elicit protective antibodies 
against three major filoviruses as well as potentially cross- protective cellular immunity25. 
MVA is an attenuated poxvirus derived by more than 500 serial passages in chicken embryo 
fibroblast cells and contains well -studied internal deletions that account for its low virulence. 
Phase 3 trial data with the Bavarian Nordic MVA backbone demonstrat es immunogenicity 
and a reasonable side effect profile in Phase 3 clinical trials. The clinical safety profile of 
MVA -based recombinant vaccines has been established in numerous Phase 1 and Phase 2 
trials26,27. Immunogenicity studies of MVA multi -filovirus vaccine in nonhuman primates 
(NHPs) demonstrated substantial binding and neutralizing antibodies against EBOV, SUDV, 
and MARV. Some protection in MVA- BN® -Filo vaccine recipient NHPs was observed. 
However, the use of a heterologous prime -boost regimen with recombinant adenovirus -based 
vaccines resulted in much more complete levels of protection. In these NHP studies, protection was observed regardless of the order of the prime or boost . These results led to a 
series of trials in humans combining replication- defective adenovirus vectors and 
MVA-
BN® -Filo. Under Janssen’s sponsorship, thre e Pha se 1 c linica l trials have completed re cruitment 
and da ta for the c linical study reports (CSR) are being analyzed; one Pha se 1, three Pha se 2 and 
three Phase 3 clinica l trials are ongoing and activ ely re cruiting. In addition, a fir st-in-human 
Phase 1 c linical tria l of a combina tion regimen of the multiv alent Ad26.F ilo as prime in 
combina tion with MVA- BN® -Filo as boost vacc ination is currently ong oing. In the ongoing 
clinical tria ls, MVA- BN®-Filo is administered a s prime or as boost in di fferent het erologous 
prime-boost reg imens in c ombination with Ad26.ZEB OV or Ad26.F ilo (multivalent). The 
current exper ience a mounts to mo re than 1,700 subj ects that have been enrolled i n the  completed 
and ongoing c linica l trials and no s afety con cerns have arisen from the  ongoing c linica l program.  
The current clinical study has two major objectives. First, to further chara cterize and better  
understand whether innate immune responses as measured at early time points following 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           29 
CONFIDENTIAL  
 vaccination with ChAd- EBO-Z are associated with late endpoints such as neutralizing antibody 
titers, T cell responses, and potentially protection from EVD . Second, to evaluate the effect of 
homologous or heterologous boosting, with a short interval employed between prime and boost 
vaccination. The advantage of the short interval is that it minimizes the risk of post-immunization anti-vector (ChAd3) antibodies interfering with the boost response, and differs 
from other studies such as 14 -day intervals as tested in [STUDY_ID_REMOVED] in which the adaptive 
response had already evolved significantly. A short interval also has the potential advantage of 
accelerating the development of immune responses for those at risk in an outbreak setting or for aid workers deployed to outbreak areas. This trial will employ systems biology tools
28, in 
addition to immunology and clinical chemistry methods, to explore whether the kinetics, magnitude and profile of host responses following first and second vaccination can provide insights in to potential mechanisms of protection and the differences between protective and non -
protective states.
 
2.3. Potential Risks and Benefits 
2.3.1. Potential Risks  
The potential risks to subjects due to participation in the study are those associated with 
venipuncture, intramuscular injection (IM), and possible reactions to the experimental vaccine (s) 
or placebo. There may be potential risk related to breach of confidentiality, as well as other 
unknown ri sks, discomforts, or side effects.  
Venipuncture causes transient discomfort and may result in fainting. Fainting is usually transient 
and managed by having the subject lie down and elevate his/her legs. Bruising at the site of the 
venipuncture may occur but may be prevented or lessened by applying pressure to the site for 
several minutes. Venipuncture may also cause infection. The use of aseptic (sterile) technique 
will make infection at the site where blood will be drawn extremely unlikely.  
Intramuscular injection may cause transient discomfort and fainting. Giving an IM injection may 
predispose a subject to infection. However, the use of sterile technique will make an infection at 
the injection site extremely unlikely.  
Acute and potentially life- threatening allergic reactions (e.g., anaphylaxis) are also possible as a 
result of vaccination. Very rarely there can be a serious allergic reaction. These reactions can manifest as skin rash (hives); swelling around the mouth, throat, or eyes (angioedema); diffic ulty 
breathing (bronchospasm), a fast pulse (tachycardia), or drop in blood pressure (hypotension). If these reactions occur, they can be usually stopped by the administration of emergency medications by the study personnel. As with any vaccine or medicati on, there is a very small 
chance of a fatal reaction (death), although researchers do not expect this to occur.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           30 
CONFIDENTIAL  
 In general, uninfected subjects who participate in Ebola vaccine studies may develop Ebola-
specific antibodies as a result of an immune response to the candidate Ebola vaccine, referred to 
as vaccine induced seropositivity (VISP). These antibodies may be detected in Ebola serologic 
tests, causing the test to appear positive even in the absence of actual Ebola virus infection. VISP 
may become evident during the study, or after the study has been completed. Subjects should not donate blood for 3 months after receiving  the second study vaccine.  
It is unknown if MVA- BN® -Filo or ChAd3 -EBO -Z vaccines pose risk to egg, conception, 
pregnancy, an unborn child , or a breastfeeding infant.  Women of childbearing potential who are 
not sterilized via tubal ligation , bilateral oophorectomy , hysterectomy, successful Essure® 
placement (permanent, non-surgical, non- hormonal sterilization) with history of documented 
radiological confirmation test at least 90 days after the procedure (or with use of another birth control method if history of confirmation test not confirmed, still menstruating, or < 1 year of the last menses if menopausal must agree to practice effective contraception for a minimum of 30 
days prior to study product exposure and agree to practice effective contraception for the duration of study product exposure, including 90 days after the second  study vaccination. If a 
female subject becomes pregnant while participating in this trial, we will ask permission to 
follow -up about her health through pregnancy outcome and the health of her baby.  
Subjects will be asked  to provide protected health information (PHI). All attempts will be made 
to keep this information within the limits of the law. However, there is a chance that unauthorized persons will see the subjects’ PHI. All records will be kept in a locked file cabi net 
or maintained in a locked room at the Cincinnati Children’s Hospital Medical Center (CCHMC) 
Vaccine and Treatment Evaluation Unit ( VTEU ) site. Electronic files will be password protected. 
Only people who are involved in the conduct, oversight, monitoring, or auditing or this study 
will be allowed access to PHI that is collected. Any publications from this study will not use 
information that will identify subjects by name. Organizations that may inspect and/or copy 
research records maintained at the part icipating VTEU sites for quality assurance (QA) and data 
analysis include groups such as the National Institute of Allergy and Infectious Diseases (NIAID) and the FDA.  
The MVA- BN® -Filo and ChAd3 -EBO- Z vaccines are currently under investigation for use in 
humans.Chimpanzee adenovirus Type 3 (‘ChAd3’, or VRC designation ‘cAd3’) is a subgroup C adenovirus with properties similar to those of human Ad5. Serological studies showed a low seroprevalence in human sera for antibodies to ChAd3 and when present, antibody titers  were 
low
29. In addition, Ad5 pre-existing immunity did not appear to cross -react with ChAd3 in 
mice30. 
ChAd3 -EBO -Z 
Recombinant, replication -defective ChAd3 -EBO-Z- based vaccines have been shown capable of 
inducing an immune response comparable to Ad5- based vaccines in mice30,31. In two  Phase 1 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           31 
CONFIDENTIAL  
 studies with an investigational recombinant ChAd3- vectored hepatitis C virus (HCV) vaccine, at 
total of 65 healthy adults were vaccinated by IM injection with doses up to 7.5x1010 pu [studies 
HCV 001 and HCV 003; ClinicalTrials.gov identifiers [STUDY_ID_REMOVED] and [STUDY_ID_REMOVED], 
respectively]. Several prime -boost schedules were evaluated with 4 -11 subjects per group. 
Mostly mild, self -limiting local and systemic reactogenicity was observed which was dose-
dependent but did not differ significantly between priming and boosting and overall, these vaccines were assessed as having an acceptable safety profile. The vaccinations induced HCV -
specific immunity with broad specificity that was sustained for at least a year after the boost with heterologous adenoviral vector
32,33. 
Since the beginning of ChAd3- EBO-Z‘s development (IBD 09 September 2014), it has been 
administered to 3421 healthy study participants from the age of 1 and above in doses up to 
1x1011 pu. Note that 1 x 1011 pu as used in these studies is equivalent to 2 x 1011 vp.  The 
present protocol uses the vp designation.  The summary below was generated from data available through 08 September 2017, from subjects enrolled in Phase 1 and Phase 2 studies. For more detailed safety information please refer to the product IB.  
Safety in Phase I Studies :  
For dose selection, four clinical Phase 1 studies assessing  the investigational monovalent 
ChAd3 -EBO -Z vaccine  have been completed. In these studies, 271 healthy adults received one 
dose of ChAd3 -EBO- Z vaccine at one of four different doses ranging from 1x10
10 pu to 1x1011 
pu. In one of these studies (study VRC207), 2 different doses of the bivalent investigational ChAd3 -EBO vaccine (2x10
10 pu and 2x1011 pu) were  assessed as well, and in 2 of the studies 
(EBL01 and EBL03)22 heterologous boosting with the multivalent MVA- vectored vaccine 
MVA- BN® -Filo (containing an insert for EBOV GP, as well as the SUDV GP, the Musoke 
strain MARV glycoprotein, and a nucleoprotein from the TAFV) were  assessed.   
Published data from VRC 207 reported mild to moderate reactogenicity and no SAEs. An artificially prolonged aPTT was seen in three volunteers but was found to be an effect on the laboratory assay and not clinically significant 
20. Published data from EBL01 reported mostly 
mild reactogenicity and no SAEs 21. Published data from the Mali1000 (EBL03) reported 
solicited AEs observed for 7 days following booster vaccination with MVA- BN® -Filo included 
local pain and tenderness, fever, fatigue, myalgia, arthralgia, headache and chills. There were no 
SAEs following boost with MVA- BN® -Filo or saline placebo. Serological responses of the 
MVA- BN® -Filo booster participants showed that the GMT 28 days after boosting was 
significantly higher than that 2 8 days after priming for the 27 participants boosted with MVA-
BN® -Filo22. 
No Grade 3 local solicited AEs were reported in any of the dose groups in any of the initial 
Phase 1 trials  that have evaluated ChAd3- EBO-Z. Pain was the most frequently reported Grade 2 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           32 
CONFIDENTIAL  
 local AE reported with a variable range by trial and not clear trend for an increase by dose. Pain 
was also the most frequently reported Grade 1 local AE with a variable range by trial and 
increasing lower li mit by dose [0 -10.5%] with 1x1010 pu, [0-10.0%] with 2.5x1010 pu, [0-15.0%] 
with 5x1010 pu, and [0-9.1%] with 1x1011 pu. 25.0% of the subjects in the placebo group in the 
study ChAd3 -EBOZ Lau ( Lausanne) (only trial with a placebo control group) reported Grade 1 
pain. 
Grade 3 systemic solicited AEs were reported sporadically with 2.5x1010 and 5x1010 pu, and 
none were reported with 1 x1011 pu. Systemic AEs occurred mostly within 24 hours after 
vaccination and were generally self -limiting within  24 hours. Overall, a trend for an increase in 
systemic AEs by increasing dose was observed: 1x1010 pu (70.0% in VRC207 and 50.0% in 
EBL03) and 1x1011 pu (80.0% in VRC207 and 63.6% in EBL03) across trials. 
Fever within 7 days post-vaccination was observed in 5% of the subjects in the control group, in 
none of the subjects who received the 1x1010 pu dose, in 14.2% of the subjects who received 
2.5x1010 pu, in 19.2% of the subjects who received 5x1010 pu and in 38.1% of t he subjects in the 
1x1011 pu groups. The only Grade 3 fever occurred with 5x1010 pu in the study ChAd3 -EBOZ 
Lau. The onset of fever was mostly on Day 0-1 (except for 6 cases on Day 3- 6) and fever was 
mostly self -limiting within 1 day. There was a clear dose- dependent increase in fever (any 
grade). 
Transient non -clinically significant lymphopenia, neutropenia and anemia were observed within 
the first 28 days post vaccination with all doses (except neutropenia with 1x1011 pu) across all 
trials (including lymphopenia and neutropenia in the placebo control group in the study ChAd3 -
EBOZ Lau [only trial with a placebo control group]). The majority of these events were Grade 1. 
There is no evidence suggesting that the magnitude of  these non- clinically significant changes 
increases with increasing vaccine dose.  
Seven cases of transient platelet count drops met as per protocol criteria for thrombocytopenia 
(<150x109/L), 4 in subjects who received 2.5x1010 pu and 3 in subjects who received 5x1010 pu. 
No clinical signs or symptoms suggestive of increased tendency for bleeding were reported. No thrombocytopenia was reported with 1x10
10 and 1x1011 pu. Transient non- clinically significant 
drops in platelet  count within 7 and within 28 days post- vaccination not meeting criteria for 
thrombocytopenia seem to be induced by vaccination (‘real’ phenomenon) i.e. seen consistently across trials and seen less frequently with in the placebo group included in the study ChAd3 -
EBOZ Lau.  
No significant related unsolicited AEs were reported with any of the doses in any of the trials. No Suspected Unexpected Serious Adverse Reaction s were reported. The only SAE reported to 
date (peritoneal tuberculosis 14 days post vaccination) is considered unrelated to v accination. 
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           33 
CONFIDENTIAL  
 Safety in Phase II Studies:  
Two phase II studies of ChAd3- EBO -Z have been performed, EBOLA Z CHAD3-004 and 
EBOLA Z CHAD3 -005, encompassing both pediatric and adult age groups. Grade  3 local 
solicited adverse events (AEs)  were reported in 0.4% adult and 1.3% pediatric subjects in the 
EBO-Z group. Pain was the most frequently reported solicited local AE. Pain was reported by 
47.6% in adult and 31.2% in pediatric subjects (ranging from 31.0% to 54.5%) in the EBO- Z 
group and 7.6% in adults and 20.0% subjects in the control group in pediat rics (ranging from 
14.0% to 23.2%). 
Systemic AEs occurred  mostly  within 24 hours after vaccination and were generally self- 
limiting within 24 hours. Grade 3 systemic solicited AEs were reported by 2.8% in adult and 
51.3% in pediatric subjects in EBO -Z group, and 0.8% in adult and 16.7% in pediatric subjects in 
the control group. In adults, the  most  commonly  reported mild to moderate systemic AEs were 
headache and fatigue; 46.1% and 38.0% subjects in the EBO-Z group and 18.1% and 12.5% 
subjects in control group, respectively.  
Thrombocy te count  drops from baseline levels (the majority  of them occurring within the 
normal range) were observed in the EBO-Z and the control group in adult and pediatric subjects 
without notable differences between groups, and no clinical signs of thrombocytope nia (AESI) 
were reported within the first 7 da ys pos t-vaccination in either of the groups. 
Unsolicited AEs were reported by 16.4% of adult and 13.7% of pediatric subjects in the  
EBO-Z group and 15.8% of adult and 8.0% pediatric subjects in the control group. Grade 3 
unsolicited AEs that were considered to be related to the stu dy vaccination by the I nvestigator 
were reported by 0.9% subjects in the EBO-Z group and 0.1% subject in the control group in adults and no Grade 3 unsolicited AEs were reported in pediatric s. 
Among the adult subjects, SAEs were reported by 11 (0.7%) subjects in the EBO-Z group and 
18 (1.2%) subjects in the Placebo/ EBO-Z group over the one ye ar follo w-up period. No SAE  
was considered to be related to the s tudy vaccination per the Investigator’s judgement.  
For complete safety information from phase II trials please refer to the product IB.  
MVA- BN®  and MVA- BN®-Filo 
MVA-BN® and the MVA-BN® based r ecombin ant vaccin es including MVA- BN® -Filo are 
highly a ttenuated, replication defective st rains of vaccinia  that are unable to repli cate in human 
cells. Th erefore, they ca nnot be t ransmitted or cause disper sed va ccinia infection. 
BN has performed an extensive nonc linica l development prog ram for MVA -BN®  demonst rating 
the safety a nd efficacy of MVA- BN® . Since BN initiated c linica l developm ent of MVA -BN® in 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           34 
CONFIDENTIAL  
 2001, more than 10,500 subj ects h ave been va ccinated with MVA-BN® and MVA-BN® based 
recombin ant vaccines in c linica l trials sponsore d by B N, Janssen, the NI H and other third-par ty 
sponsors. MVA -BN® -Filo vaccine has been studied in test tubes and in animals and has been 
used in limited numbers of people so far. Safety information was combined from 239 
participants who received MVA -BN® -Filo in the first four studies. In general, MVA -BN® -Filo 
has been shown to be well- tolerated.  
Across all clinical tria ls, no trends f or unexpected and/or s erious susp ected adver se reactions due 
to the inve stigational produc t were det ected. MVA-BN® and its recombi nant der ivatives have 
been shown to be s afe in healthy as we ll as in immunocompr omis ed popula tions th at are 
contraindicated to receive conve ntion al, re plication competent vacc inia vacc ines, e.g., 
individua ls with HIV infection or  diagnosed with atopic dermatitis . More over, the safety of 
MVA-BN® was confirmed in an e lderly population up to 80 ye ars of age. No dif ference in the  
safety profile has been observed be tween v accini a-naïve a nd vaccinia-exper ienced subjects 
receiving  MVA-BN®. 
To date, more than 7,800 subjects have received at least one vaccination with MVA- BN® i n 
completed and ongoing clinical trials. A total of seven serious suspected adverse drug reactions 
(sarcoidosis, Crohn’s disease, transitory ocular muscle paresis,  congestive heart failure due to 
cardiomyopathy, pneumonia and pleurisy, hypersensitivity, and non- ST segment elevation 
myocardial infarction) have been reported for MVA -BN® so far (7 out of 7,871 vaccinated 
subjects = 0.09%). All of them have been thoroughly reviewed by BN and the trial specific Data 
and Safety Monitoring Board (DSMB), who concluded that the continued use of MVA- BN® in a 
clinical setting presented no special risks to the subjects.  
None of the severe adver se reactions a ssociated w ith replicating VV (vaccinia vir us) smallpox 
vaccin es, such a s progre ssive vaccini a, eczema vaccinatum, gene ralized va ccinia  and inadv ertent 
(auto) inoc ulation have b een re ported in any of the c linical tria ls with M VA-BN®. Given tha t 
MVA-BN® is replication incompetent in ma mmalian ce lls, it can e ssentially be rule d out tha t 
MVA-BN® would induce these side ef fects associated with re plication compete nt VV34. 
Importantly , MVA-BN® does not in crease the r isk for developing myo- /pericarditis, in cont rast 
to the older, replication -competent vaccinia based  vaccines. Despite close cardiac monitoring, no 
case of confirmed myocarditis has been reported in the 7,871 subjects vaccinated with the backbone vector MVA- BN® so far.  Only 1 possible, albeit doubtful, case of pericarditis 
(consisting of chest pain only, with no other cardiac findings suggestive of pericarditis) has been observed in the MVA BN clinical trial program. In addition, the safety of MVA- based 
recombinant vaccines has been confirmed (using doses up to five times higher than used with 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           35 
CONFIDENTIAL  
 MVA- BN®) in  more than 900 subjects in completed clinical trials for other products than MVA -
BN®-Filo. These trials included children 6 months to 6 years  of age and high-risk populations 
like subjects with HIV infection or suffering from melanoma.  For the present study, subjects will 
be actively screened to exclude preexisting cardiac concerns.” 
MVA- BN® -Filo vaccine has been studied in animals and has been used in limited numbers of 
people so far. The ongoing clinical development program, which was initiated in Novembe r 
2014 is sponsored by Janssen. Under Janssen’s sponsorship, three Phase I clinical trials have 
completed recruitment and data for the clinical study reports are being analyzed; one Phase I, three Phase II and three Phase III clinical trials are ongoing an d actively recruiting. In addition, a 
first- in-human Phase I clinical trial of a combination regimen of the multivalent Ad26.Filo as 
prime in combination with MVA -BN®-Filo as boost vaccination is currently ongoing. In the 
ongoing clinical trials, MVA -BN® -Filo is administered as prime or as boost in different 
heterologous prime-boost regimens in combination with Ad26.ZEBOV or Ad26.Filo (multivalent). The current experience amounts to more than 1,700 subjects that have been enrolled in the completed and ongoi ng clinical trials and no safety concerns have arisen from the 
ongoing clinical program. 
The prelimin ary sa fety prof ile from a  pooled s afety data analy sis from four Pha se 1 studi es 
(VAC52150EBL1001, VAC52150EBL1002, VAC52150EBL1003 and VAC52150EBL1004) 
showed tha t the majority of the unsolic ited AEs  were mild (grade 1) or moderate  (grade 2) in 
sever ity and all were tran sient in na ture and re solved without s equel ae. Two -thirds of the 
participants reported at least one local site reaction. Three -fifths of the participants reported at 
least one systemic symptom. The frequency of local and solic ited sy stemic AEs is simil ar to that 
seen with other inj ectable vacc ines, with the  most frequent being lo cal pain and head ache, fatigue 
and myalgia. Overall, no clinically significant trend in laboratory assays was found. Grade 3 
laboratory abnormalities reported included hyperkalemia, hypokalemia, decreased hemoglobin, 
decreased neutrophils, decreased platelets and proteinuria. These cases were isolated and no common trend was found. One subject in the study VAC52150EBL2001 experienced a serious and very rare condition called “Miller Fisher syndrome”. This condition consists of double vision, pain on moving the eye, and difficulty with balance while walking. Miller Fisher syndrome most commonly occurs following a recent inf ection. The subject experienced these 
symptoms about a week after suffering from a common cold and fever. The event happened about a month after boost vaccination with either MVA- BN®-Filo or placebo. This subject had 
to go to the hospital for treatment and  has recovered. After an extensive investigation, the event 
has been considered to be doubtfully related to vaccine and most likely related to the previous common cold. 
In conclusion, the available nonclinical and clinical data showed no unexpected findings and no 
target organ toxicity. MVA- BN® and MVA- BN® based recombinant vaccines, including MVA- 
BN® -Filo,have demonstrated a very good safety profile combined with the ability to induce 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           36 
CONFIDENTIAL  
 strong immune responses. Furthermore, available data in subjects with contraindications to 
conventional vaccinia vaccines such as patients with atopic dermatitis ( AD) and HIV infection 
revealed no special risks or safety concerns following MVA -BN® handling and administration.  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov , as required 
by US Law. This web site will not include information that can identify subjects. This web site will include a summary of the results in a tabular format in cluding participant flow; demographic 
and baseline characteristics; primary outcomes, as well as results of any scientifically appropriate 
statistical tests; and adverse event information.  
2.3.2. Known Potential Benefits  
There are no known benefits from receiving MVA- BN® -Filo or ChAd3 -EBO-Z, but there is the 
prospect of benefit. Subjects may develop immune responses to filoviruses, but they may not be 
protected. Society may benefit from the potential development of a new vaccine regimen against filoviruses. In addition, information learned from this study may impact overall understanding of 
cellular and immunologic processes before and after vaccination and generate other hypotheses 
that may impact future vaccine development.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           37 
CONFIDENTIAL  
 3 OBJECTIVES AND OUTCOME MEASURES  
3.1. Study Objectives  
3.1.1. Primary  
• Assess the safety and reactogenicity of study products by study group when administered IM 
to healthy adults. 
3.1.2. Secondary  
• Assess the antibody response to Zaire ebolavirus (EBOV) glycoprotein (GP) by study group.  
3.1.3. Exploratory ( if applicable ) 
• Assess the EBOV neutralizing antibody titers by study group.  
• Assess antibody functionality by antibody-dependent cell- mediated cytotoxic ity (ADCC) 
responses by study group.  
• Assess activation of CD4+ and CD8+ T cells in multiple cell subpopulations by study group.  
• Assess inflammation via cytokine secretion and C-reactive protein (CRP) by study group.  
• Assess EBOV GP -specific T cell respon ses by study group.  
• Assess ChAd3 -specific T cell responses by study group.  
• Assess plasmablast frequencies by study group.  
• Assess B -cell receptor (BCR) repertoire by study group.  
• Assess and characterize change in gene expression in PBMCs by study group.   
• Identify gene expression changes associated with adaptive humoral and/or cellular immune responses.  
3.2. Study Outcome Measures  
3.2.1. Primary  
• Frequency and severity of solicited local and systemic reactogenicity from the time of study 
vaccine administration through 7 days post-vaccination. 
• Frequency and severity of vaccine- related unsolicited adverse events (AEs) from the first 
study vaccination through 28 days post second vaccination. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           38 
CONFIDENTIAL  
 • Frequency and severity of clinical safety laboratory AEs fr om the time of first study 
vaccination through approximately 28 days after the second vaccination.  
• Frequency of Serious Adverse Events (SAEs) and vaccine -related Medically Attended 
Adverse Events (MAAEs) through 6 months post first vaccination. 
3.2.2. Secondary  
• Seroconversion defined as anti-EBOV GP ELISA titer > 50 if baseline (Day 1) titer ≤ 50 or 
fold rise > 4 as compared to baseline if baseline titer > 50 on Day 8, 15, 22, 29 and 36.  
• Geometric mean titer (GMT) on Day 1, 8, 15, 22, 29 and 36 as measured by anti- EBOV GP 
ELISA.  
• Geometric mean fold rise (GMFR) in titer on Day 8, 15, 22, 29 and 36 compared to baseline 
(Day 1) as measured by anti -EBOV GP ELISA.  
3.2.3. Exploratory  
• GMT of neutralizing antibodies to EBOV GP at Day 1, 8 and 15 as measured by EBOV GP pseudovirion neutralization assay.  
• GMFR in titer on Day 8 and 15 compared to baseline (Day 1) as measured by EBOV GP pseudovirion neutralization assay.  
• Change in the percent age of killed cells as measured by ADCC on Day 8, 15, 22, 29, and 36 
compared to basel ine (Day 1).  
• Change in percentage of activated CD4+ and CD8+ T cells for each cell subpopulation on Day 8 and 15 compared to baseline (Day 1) as measured by flow cytometry.  
• Change in cytokine concentration and CRP on Day 2, 3, 4, 6, 8, 9 and 15 compared to baseline (D ay 1) as measured by Luminex assay and clinical laboratory CRP assay, 
respectively.  
• Change in percentage of EBOV GP -specific cytokine secreting CD4+ and CD8+ T cells on 
Day 8, 15, 22, and 36 compared to baseline (Day 1) as measured by intracellular cytokine staining (ICS).  
• Change in percentage of EBOV GP -specific CD4+ and CD8+ T cells on Day 8  and 15 as 
compared to baseline (Day 1) measured by tetramer staining for predominant human leukocyte antigen (HLA) types.  
• Change in percentage of ChAd3- specific cytokine secreting CD4+ and CD8+ T cells on Day 
8, 15, 22 and 36 compared to baseline (Day 1) as measured by ICS. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           39 
CONFIDENTIAL  
 • Change in percentage of CD19+CD27+CD38+ plasmablasts on Day 8 and 15 compared to 
baseline (Day 1) as measured by flow cytometry. 
• Change in B- cell repertoire (BCR) on Day 8 and 15 as compared to baseline (Day 1) from 
sorted CD19+ CD27+ CD38+ plasmablasts as measured by immunoglobulin heavy chain sequencing.  
• Characterization of antigen -specific BCR as measured by yeast display on day 36.  
• Change in gene expression in PBMCs on Day 2, 3, 4, 6, 8, 9, and 15 compared to baseline 
(Day 1) as measured by RNA -Seq.  
• Identification of gene expression changes on Day 2, 3, 4, 6, 8, 9, and 15 associated with each 
subject’s peak change in percentage of EBOV GP -specific cytokine secreting CD4+ and 
CD8+ T cells across Day 15, 22, and 36.  
• Identification of gene expression changes on Day 2, 3, 4, 6, 8, 9, and 15 associated with each subject’s peak anti-EBOV GP ELISA titer across Day 15, 22, 29, and 36.  
• Identificatio n of gene expression changes on Day 2, 3, 4, 6, 8, 9, and 15 associated with each 
subject’s EBOV neutralizing antibody titer at Day 15.  
•  Identification of gene expression changes on Day 2, 3, 4, 6, 8, 9, and 15 associated with each 
subject’s peak percent age of killed cells as measured by ADCC across Day 15, 22, 29, and 
36.   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           40 
CONFIDENTIAL  
 4 STUDY DESIGN 
This is a Phase 1, randomized, double-blind trial of 60 males and non-pregnant females, 18-45 
years old, inclusive, who are in good health and meet all eligibility criteria. This trial is designed 
to assess the safety, reactogenicity and immunogenicity of a Zaire ebolavirus  vaccine (ChAd3 -
EBO- Z) for the prevention of EVD. Vaccine will be administered intramuscularly in a single 
dose regimen on Day 1 followed by a booster dose at Day 8 for all groups (group 1: placebo boost, group 2: ChAd3- EBO-Z boost, group 3:  MVA -BN
®-Filo boost).   
Potential subjects will be screened by history, physical exam, EC G, vital signs, height and 
weight, and clinical laboratory tests  (refer to Appendix A : SUPPLEMENTS/APPENDICES) 
prior to enrollment.  
Subjects will be randomized in double-blind fashion to 1 dose of ChAd3- EBO- Z vaccine at Day 
1 followed by a boost at Day 8. Doses will be administered per the schedule outlined in the Table 
1 below. 
Table 1: Treatment Arms  
Treatment Arm  Subjects 
Enrolled (n)  Day 1  Day 8  
1 20 2 x 1011 vp ChAd3 -EBO -Z Placebo  
2 20 2 x 1011 vp ChAd3 -EBO -Z 2 x 1011 vp ChAd3 -EBO -Z 
3 20 2 x 1011 vp ChAd3 -EBO -Z 1 x 108 IU MVA -BN®-Filo 
Total  60 subjects  
On vaccination days, all females of childbearing potential will have a urine pregnancy test done. 
All subjects will have baseline vital signs, targeted physical examination, clinical safety laboratory tests (refer to Appendix A : SUPPLEMENTS/APPENDICES) done, and antibody 
levels measured. Vaccine or booster will then be administered by intramuscular injection into the 
deltoid muscle. Subjects and study staff will be blinded to treatment arm. Venous blood will be 
collected for high resolution HLA typing for Class 1 (A, B, and C locus) testing  on Day 1 prior 
to vaccination. 
Reactogenicity will be measured by the occurrence of solicited injection site and systemic AEs. 
Subjects will maintain a memory aid through 7 days post each vaccination, recording temperature, solicited local and systemic symptoms. Unsolicited non-serious AEs will be 
collected from the time of first study vaccination through approximately 28 da ys after the second  
study vaccination. Serious AEs and MAAEs occurring from the time of the first  study 
vaccination through approximately 6 months after the first study vaccination will be collected. 
Clinical safety labs will be collected on Day 1, 8, 15, 29, and 36; if labs are abnormal, they will 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           41 
CONFIDENTIAL  
 be assessed, documented, reported, and followed  until the lab returns to the subject’s baseline value 
or has stabilized.   
Immunogenicity testing will be performed as outlined in Section 8.2.2. Blood will be collected  
for future exploratory assays  as described in Section  8.2.2 and Appendix A : Schedule of Study 
Procedures and Evaluations . The duration of this trial for each subject will be approximately 6 
months. 
For additional details on study procedures and evaluations by study visits/days, see Section 7 and 
Appendix A : Schedule of Study Procedures and Evaluations. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           42 
CONFIDENTIAL  
 5 STUDY ENROLLMENT AND WITHDRAWAL  
Sixty  male s and non-pregnant females, 18-45 years old, inclusive, who are in good health and 
meet all eligibility criteria, will be enrolled from a single Vaccine and Treatment Evaluation Unit 
(VTEU ) site. The target population should reflect the community at large at the participating 
VTEU site. Estimated time to complete enrollment in this trial is approximately 5  months. 
Information regarding this trial may be provided to potential subjects who have previously 
participated in va ccine trials conducted at the participating VTEU site. Other forms and/or 
mechanisms of recruitment may also be used. The local Institutional Review Board (IRB) will approve all materials prior to use.  
Subject Inclusion and Exclusion Criteria must be assessed by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site principal investigator or sub-investigator.  
No exemptions are granted on Subject Inclusion/Exclusion Criteria in DMID- sponsored studies.   
Questions about eligibility will be directed toward the DMID Medical Officer.  
5.1. Subjec t Inclusion Criteria  
Subjects eligible to participate in this study must meet all of the following inclusion criteria:  
1. Provide written informed consent before initiation of any study procedures.  
2. Are able to understand and comply with planned study procedures and be available for all 
study visits/phone calls. 
3. Males or non -pregnant females ages 18 -45, inclusive. 
4. Subject must have a body mass index (BMI) ≥18.5 and <35 kg/m2.  
5. Are in good health* 
* As determined by medical history and physical examination to evaluate acute or currently ongoing chronic 
medical diagnoses or conditions, defined as those that have been present for at least 90 days which would affect 
the assessment of the safety  of subjects or the immunogenicity of study vaccinations. Chronic medical diagnoses 
or conditions should be stable for the last 60 days (no hospitalizations, ER or urgent care for condition and no 
adverse symptoms that need medical intervention such as medication change/supplemental oxygen). This includes no change in chronic prescription medication, dose, or frequency as a result of deterioration of the chronic medical diagnosis or condition in the 60 days prior to enrollment. Any prescription change that is due to change 
of health care provider, insurance company, etc., or that is done for financial reasons, as long as in the same class of medication, will not be considered a deviation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or 
appropriate sub- investigator, will not be considered a deviation of this inclusion criterion. Subjects may be on 
chronic or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           43 
CONFIDENTIAL  
 and do not indicate a worsening of medical diagnosis or condition. Similarly, medicati on changes subsequent to 
enrollment and study vaccination are acceptable provided there was no deterioration in the subject’s chronic 
medical condition that necessitated a medication change, and there is no additional risk to the subject or interference wi th the evaluation of responses to study vaccination. Note: Topical, nasal, and inhaled medications 
(apart from steroids as outlined in the Subject Exclusion Criteria), herbals, vitamins, and supplements are 
permitted.  
6. Oral temperature is less than 100.0 °F (37.8oC). 
7. Pulse is 47 to 105 beats per minute (bpm), inclusive. 
8. Systolic blood pressure (BP) is 85 to 150 mm Hg, inclusive. 
9. Diastolic blood pressure (BP) is 55 to 95 mm Hg, inclusive. 
10. Have acceptable screening laboratories#& within 28 days prior to enrollment (Refer to 
Appendix C  for acceptable screening values.)  
# Screening labs include white blood cell (WBC), Hgb, platelet count, ANC, sodium, potassium, 
creatinine,  albumin, total protein, PT, PTT, alanine aminotransferase (ALT). Blood Urea 
Nitrogen (BUN) will be obtained only if creatinine is above normal range . 
& Screening laboratory values that are outside the range of eligibility but are thought to be due to 
an acute condition or due to laboratory error may be repeated once.  [see Manual of Procedures 
(MOP)]  
11. Have normal screening laboratories for urine protein. Trace protein is acceptable.  
12. Drug screen for opiates is negative.  
13. Hemoglobin A1C ( HgbA1C) <6.3% at screening. 
14. HIV 1/2 antibody negative. 
15. HCV antibody negative. 
16. HBsAg negative.  
17. Women of childbearing potential‡, must be using an effective method of contraception§ from 
30 days prior to the first study vaccination until 90 days after the second  study vaccination. 
‡ Not s terilized via tubal ligation, bilateral oophorectomy, hysterectomy,successful Essure® placement (permanent, 
non-surgical, non -hormonal sterilization) with history of documented radiological confirmation test at least 90 
days after the procedure  (or with us e of another birth control method if history of confirmation test not 
confirmed),  still menstruating , or < 1 year of the last menses if menopausal.  
§ Includes, but is not limited to, non -male sexual relationships, abstinence from sexual intercourse with a male 
partner, monogamous relationship with a vasectomized partner, male condoms with the use of applied 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           44 
CONFIDENTIAL  
 spermicide, intrauterine devices, NuvaRing®, and licensed hormonal methods such as implants, injectables or 
oral contraceptives (“the pill”).  
18. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to each study vaccination. 
19. Women agree to not donate eggs (ova, oocytes) from the start of sc reening onwards until at 
least 90 days after the second vaccination.  
20. Agrees not to participate in another clinical trial during the study period.  
21. Agrees not to donate blood to a blood bank for 3 months after receiving the second  study 
vaccine.  
5.2. Subject Exclusion Criteria 
Subjects eligible to participate in this study must not meet any of the following exclusion criteria:  
1. Women who are pregnant, planning to become pregnant or lactating*. 
* Includes breastfeeding or planning to breastfeed at any given time from the receipt of study vaccination through the 6-month trial period.  
2. Known allergy or history of anaphylaxis, severe local or other serious adverse reactions to vaccines or vaccine products
%, or history of severe allergic reactions.  
% Includes a known allergy to egg, egg products and aminoglycosides or any of the constituents of the study 
vaccines [e.g., polysorbate 80, ethylenediaminetetraacetic acid (EDTA), L -histidine, tris (hydroxymethyl) -
amino methane (THAM)).  
3. Received an experimental agent5 within 3 months prior to Day 1 , or expects to receive an 
experimental agent6 during the 6- month trial -reporting period.  
5 Including vaccine, drug, biologic, device, blood product, or medication.  
6 Other than from participation in this study.  
4. Received immunoglobulin or other blood product within 3 months before enrollment in this study. 
5. Received any licensed live vaccine within 30 days prior to the first  study vaccination  through 
30 days after the second study vaccination. 
6. Received a licensed inactivated vaccine within 14 days prior to the first study vaccination through 14 days  after the second study vaccination.  
7. Has been vaccinated with an Ebola vaccine.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           45 
CONFIDENTIAL  
 8. Has been diagnosed with Ebola disease, or exposed to Ebola virus including travel to West 
Africa ^ in 2014-2016.  
^ West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, Nigeria, and Sierra Leone.   
9. Known or suspected receipt of ChAd3 -EBO-Z or other ChAd3- vectored vaccine. 
10. Known or suspected receipt of an adenovirus serotype 5 (Ad5)- based vaccine.  
11. Known or suspected receipt of any licensed or investigational small pox (vaccinia) -based 
vaccine#.  
# Includes any MVA -based candidate vaccine (Imvamune or Imvanex), Dryvax, or Acam2000.  
12. Has a typical vaccinia scar.  
13. Confirmed Asplenia/Functional Asplenia.  
14. A history of bleeding or clotting disorders. 
15. Thyroidectomy or thyroid disease requiring medication during the last 12 months.   
16. History of chronic urticaria (recurrent hives).  
17. Individuals in whom the ability to observe possible local reactions at the eligible injection 
sites ( left and right deltoid region) is, unacceptably obscured due to a physical condition or 
permanent body art. 
18. Have an acute illness#, as determined by the site PI or appropriate sub-investigator, within 72 
hours prior to study vaccination. 
# An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the 
opinion of the site PI or appropriate sub -investigator, the residual symptoms will  not interfere with the ability 
to assess safety parameters as required by the protocol. Subjects may re -screen after an acute illness is 
resolved . 
19. Any confirmed or suspected immunosuppressive or immunodeficient condition* or use of anticancer chemotherapy  or radiation therapy (cytotoxic) within 3 years prior to study 
vaccination  
* including HIV infection . 
20. Administration of chronic (defined as more than 14 days) immunosuppressants or other immune modifying drugs within 6 months of receipt of study vaccine. 
21. Have taken oral or parenteral (including intraarticular) corticosteroids of any dose within 30 
days prior to study vaccination. 
22. Have taken high-dose
3 dose inhaled corticosteroids within 30 days prior to study vaccination.   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           46 
CONFIDENTIAL  
 3 High -dose defined using the inhaled high -dose reference chart (Appendix B). 
23. Have a history of convulsions or encephalomyelitis within 90 days prior to study vaccination.  
24. Current or past history of alcohol or drug abuse in the last 5 years. 
25. Subjects with autoimmune disorders, chronic inflammatory disorders or neurological 
disorders with a potential autoimmune correlation.  
26. Have any diagnosis, current or past, of schizophreni a, bipolar disease, or other psychiatric 
diagnosis that may interfere with subject compliance or safety evaluations.  
27. Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 10 years prior to study vaccination. 
28. Have received any antiviral within 3 days of study vaccination 
29. History of myocarditis, pericarditis, cardiomyopathy, transient ischemic attack or stroke, myocardial infarction, angina, coronary artery disease, congestive heart fail ure, clinically 
significant arrhythmia *  
* including any arrhythmia requiring medication, treatment, or clinical follow -up. 
30. Electrocardiogram (ECG) with clinically significant findings .* 
* Clinically  significant findings include the following:  
a. Conduction disturbance (complete left or complete right bundle branch block or nonspecific intraventricular conduction disturbance with QRS ≥120 ms, PR interval ≥210 ms, any second - or third -
degree atrioventricu lar block, or prolongation of the QT interval corrected according to Bazett’s formula 
[QTcB] [>450 ms]) . 
b. Significant repolarization (ST -segment or T -wave) abnormality.  
c. Significant atrial or ventricular arrhythmia; frequent atrial or ventricular ectopy (e.g., frequent premature atrial contractions, 2 premature ventricular contractions in a row).  
d. ST-elevation consistent with ischemia or evidence of past or evolving myocardial infarction  
31. A diagnosis of Type I or II diabetes. (A history of isolated gestational diabetes is not an exclusion criterion).  
32. Current employee or staff paid entirely or partially by the contract for this trial, or staff who are supervised by the PI or Sub- Investigators.  
33. Any condition that would, in the opinion of the Site Investigator or appropriate sub-investigator, is a contraindication to study participation.* 
* Including acute or chronic (persisting for at least 90 days) clinically significant medical disease or condition, that would place the subject at an unacceptable risk of injury, render the subject unable to meet the 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           47 
CONFIDENTIAL  
 requirements of the protocol, or may int erfere with the evaluation of responses or the subject’s successful 
completion of the study.  
5.3. Eligibility Criteria for Dose 2  
Subjects may not receive subsequent vaccination if any of the criteria in Section 5.4.3 are met. 
The second vaccination may be deferred until eligibility criteria , as defined in Section 5.4.3, are 
met (see section 5.4.3).  
5.4. Treatment Assignment Procedures  
5.4.1. Randomization Procedures 
Per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) guideline E6: Good Cli nical Practice (GCP), screening records will be kept at 
the participating VTEU site to document the reason why an individual was screened, but failed 
trial entry criteria. The reasons why individuals failed screening will be recorded in the 
Statistical and  Data Coordinating Center’s AdvantageEDCSM (Electronic Data Capture System).  
Once consented and upon entry of demographic data and confirmation of eligibility for this trial, the subjects will be enrolled. Subjects will be randomized 1:1:1 in double-blind fashion to 1 dose of ChAd3- EBO-Z vaccine at Day 1 followed by a booster of placebo, ChAd3- EBO- Z 
(homologous), or MVA- BN® -Filo (heterologous) at Day 8 . 
Enrollment of subjects will be done online using the enrollment module of AdvantageEDC
SM. 
The randomization code will be prepared by statisticians at the SDCC and included in the 
enrollment module for this trial. AdvantageEDCSM will assign each subject to a treatment arm 
after the demographic and eligibility data have been entered into the sy stem. A designated 
individual at the participating VTEU site will be provided with a code list for emergency 
unblinding purposes, which will be kept in a secure place. 
Instructions for use of the enrollment module are included in the AdvantageEDCSM User’s 
Guide. Manual back -up randomization procedures and instructions are provided for use in the 
event that a participating VTEU site temporarily loses access to the Internet or the online 
enrollment system is unavailable.  
Subjects who sign the informed consent form (ICF)  and are randomized but do not receive study 
vaccine may be replaced. Subjects who sign the informed consent form, and are randomized and vaccinated, and subsequently withdraw, or are withdrawn or terminated from this trial, or are lost to follo w-up may  be replaced.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           48 
CONFIDENTIAL  
 5.4.2. Masking Procedures  
This is a double- blind clinical trial. Subjects, investigators, study personnel performing any 
study-related assessments following study vaccine administration, and laboratory personnel 
performing antibody assays wi ll be blinded to treatment arm assignment (i.e., type of booster).  
Laboratory personnel performing experimental assays including antibody assays will also be 
masked to subject ID  and study visit. 
The randomization scheme will be generated by the SDCC and provided to unblinded study personnel (i.e., research pharmacists performing study vaccination preparations and unblinded study vaccine administrators) at the participating VTEU site.  To preserve blinding and mask the 
color of study product in the syri nge, the unblinded site research pharmacist will place a blinding 
tape or overlay on the syringe to mask its content. The vaccine will then be sent to an unblinded 
study vaccine administrator for administration to the subject.  
The unblinded study vaccine administrator is a study personnel member credentialed to 
administer vaccines and may also participate in dose preparation, but will not be involved in study- related assessments or have subject contact for data collection following study vaccine 
administrat ion.  
The Safety Monitoring Committee ( SMC ) may receive data in aggregate and presented by 
treatment arm. The SMC may also be provided with expected and observed rates of the expected AEs in an unblinded fashion, and may request the treatment arm be unblinded for an individual 
subject if required for safety assessment. The SMC will review grouped and unblinded data in 
the closed session only. Refer to the protocol- specific Manual of Procedures (MOP) for 
unblinding procedures. 
5.4.3. Discontinuation of Study Produc t 
There are several reasons why a study subject may be prevented from receiving the second 
vaccination. If a subject’s study vaccine must be discontinued before the end of the vaccination 
schedule, this will not result in automatic withdrawal of the subjec t from the study.  
The second  study vaccination will not be administered to a subject if any of the following criteria 
are met:  
• Pregnancy 
• Receipt of disallowed licensed vaccine, experimental product or medication (see Section 5.2) 
• New onset of illness or condition that meets the Exclusion Criteria (see Section 5.2 ) 
• Medical condition or medication change for which continued participation, in the opinion of the site principal investigator or appropriate sub -investigator, would pose a risk to the subject 
or would likely confound interpretation of the results. Note: Medication changes subsequent 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           49 
CONFIDENTIAL  
 to the first study vaccination are not exclusionary for receipt of the follow -up study 
vaccination provided there was no deterioration in the subject’s chronic medical condition 
that necessitated a medication change, and there is no additional risk to the subject or 
interference with the evaluation of responses to study vaccination. 
• Presence of signs or symptoms that could confound or confuse assessment of study vaccine 
reactogenicity.   
Note: for subjects  with transient injection site or systemic signs or symptoms, or with an acute 
illness, including an oral temperature greater than or equal to 100.0°F, follow -up study 
vaccination/s should be postponed/deferred until signs, symptoms, or acute illness have resolved, or are improving as further specified below. No study vaccine will be given outside the protocol-
specified window.   
Note for afebrile, acute illness only:  If a subject is afebrile, his/her acute illness is nearly 
resolved with only minor residual symptoms remaining, this occurs within the acceptable 
protocol-specified window for that visit, and, in the opinion of the site principal investigator or appropria te sub -investigator, the residual symptoms will not interfere with the ability to assess 
safety parameters as required by the protocol, the subject may receive the follow -up study 
vaccination without DMID Medical Officer approval.   
• Grade 3 solicited or unsolicited adverse event that is ongoing, whether or not it is improved or resolving. An unresolved or continuing Grade 1 or Grade 2 adverse event is permissible following the documented determination by the site principal investigator or appropriate sub-investigator, that it would not render study vaccination unsafe or interfere with the evaluation 
of adverse events or immunologic response. 
• Grade 3 solicited or unsolicited adverse event that occurs in the 7 days following study 
vaccination, lasts for more than 24 hours without decreasing to a Grade 1 or Grade 2, and 
does not have an  alternative etiology . 
• Any laryngospasm, bronchospasm, or anaphylaxis within 1 day after administration of study 
product that is considered related to study product. 
• Any generali zed urticaria within 3 days after administration of study product that is 
considered related to study product. 
• Serious adverse event related to the study vaccination. 
• As deemed necessary by the site principal investigator or appropriate sub -investigator fo r 
noncompliance or other reasons. 
• Subject refusal of further study vaccination.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           50 
CONFIDENTIAL  
 • Termination of this trial.  
• New information becomes available that makes further administration of the study vaccine 
unsafe.  
Subjects who receive the first study vaccine but not the second vaccination will be encouraged to 
remain in this trial for follow -up, safety  and immunogenicity assessments per Appendix A :  
Schedule of Study Procedures and Evaluations. If the scheduled visit does not include collection of blood for safety or immunogenicity, the visit may be conducted by phone call/ electronic communication (e.g., email, text message) rather than in person continuing through approximately 6 months after the first study vaccination. See the protocol- specific Manual of 
Procedures (MOP) for alternate follow -up requirements. 
Every attempt will be made to follow all adverse events, including solicited local site and 
systemic AEs, unsolic ited non- serious adverse events, SAEs  and MAAEs  ongoing at the time of 
early withdrawal through resolution as per applicable collection times defined for the specific type of adverse event.  
5.4.4. Study Withdrawal  
Subjects may voluntarily withdraw their consent for trial participation at any time and for any reason, without penalty. The site principal investigator or appropriate sub- investigator may also 
choose to remove a subject from the study. A subject may withdraw or be withdrawn from this trial for any of the following reasons:  
• Medical disease or condition, or any new clinical finding for which continued participation, in the opinion of the site principal investigator or appropriate sub -investigator, would 
compromise the safety of the  subject, or would interfere with the subject's successful 
completion of this trial, or would interfere with the evaluation of adverse events or immunologic response. 
• As deemed necessary by the site principal investigator or appropriate sub -investigator fo r 
noncompliance or other reasons. 
• Subject withdrawal of consent.  
• Subject lost to follow -up. 
• Subject dies.  
• Termination of this trial.  
• New information becomes available that makes further participation unsafe.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           51 
CONFIDENTIAL  
 In the case of subjects who fail to appear for a follow -up safety assessment, extensive effort (i.e., 
three documented contact attempts via phone calls, emails, text messages, etc., made on separate 
occasions and followed by a certified letter) will be made to locate or recall them, or at least to 
deter mine their health status. These efforts will be documented in the subject’s study records.  
5.4.5. Handling of Withdrawals 
The primary reason for withdrawal from this trial will be recorded on the Study Status data collection form. Subjects will be encouraged to complete the Early Termination Visit. The Early Termination Visit procedures are listed in Section 7.5. 
Subjects who withdraw, or are withdrawn or terminated from this trial, or are lost to follow -up 
after signing the ICF, randomization, and receipt of study vaccine may be  replaced   to ensure 
each vaccine arm has at least 20 evaluable subjects, up to a total of 60 evaluable subjects. In order to be evaluable, a subject must receive the ChAd3- EBO -Z vaccine at Visit 1 and the 
booster vaccination of either ChAd3- EBO- Z,  
MVA-BN®-Filo , or placebo o n Day 8 as determined 
by randomization. 
 
Subjects who withdraw, or are withdrawn or terminated from this trial, or are lost to follow -up 
after signing the ICF and randomization but before receipt of study vaccine may be replaced. 
5.4.6. Termination of Study  
Although the sponsor has every intention of completing this trial, it reserves the right to 
terminate this trial at any time for clinical or administrative reasons. Reasons for termination include, but are not limited to, study closure due to the recommendation after a SMC review and 
at the discretion of DMID.  
If the study is prematurely terminated by the sponsor, any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure appropriate the rapy or follow -up for the subjects, as necessary. The investigator will provide a 
detailed written explanation of the termination to the IRB/IEC.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           52 
CONFIDENTIAL  
 6 STUDY INTERVENTION/INVESTIGATIONAL 
PRODUCT  
6.1. Study Product Description  
The ChAd3- EBO- Z vaccine consists of a recombinant replication -defective chimpanzee 
adenovirus Type 3 vector engineered to express the WT GP antigen from EBOV. The vaccine is 
formulated in a buffer (without addition of a preservative). The formulation buffer, pH 7.4, is composed of 10 mM Tris, 10 mM Histidine, 5% Sucrose (w/v), 75 mM Sodium Chloride, 1 mM 
Magnesium Chloride, 0.02% Polysorbate 80 (PS-80) (w/v), 0.1 mM EDTA, and 0.5% Ethanol 
(v/v).  
The MVA -BN® -Filo vaccine is based on the highly attenuated virus vector, Modified Vaccinia 
Ankara Bavarian Nordic (IMVAMUNE
®). The recombinant vaccine encodes the glycoproteins 
of Ebola Virus Sudan, Ebola Virus Zaire, and Marburg Virus Musoke and the nucleoprotein of Tai Forest Ebola virus. The vaccine is manufactured in Chicken Embryo Fibroblas t (CEF) cells 
derived from Specific Pathogen Free (SPF) eggs in a suspension culture using serum free medium.  
6.1.1. Acquisition  
ChAd3 -EBO -Z  
ChAd3 -EBO -Z will be provided by GlaxoSmithKline.    
MVA- BN® -Filo 
MVA- BN® -Filo will be provided by Janssen Vaccines and Prevention BV in  collaboration with 
Bavarian Nordic.   
Placebo  
Placebo, 0.9% Sodium Chloride Injection, USP will be provided by the DMID Clinical Materials Services, Fisher BioServices.   
Upon request by DMID, MVA- BN® -Filo and ChAd3 -EBO- Z will be shipped to the following 
address:  
DMID Clinical Materials Services  
Fisher BioServices  
20439 Seneca Meadows Parkway 
Germantown, MD 20876 
Phone: 240-477-1350 
Fax: 240- 477-1360 
Email: DMID.CMS@Thermo Fisher.com  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           53 
CONFIDENTIAL  
 MVA- BN® -Filo, ChAd3 -EBO- Z and placebo will be provided through the DMID Clinical 
Materials Services to the participating VTEU site prior to the start of this trial upon request and 
with prior approval from DMID. Should the site principal investigator require additional vaccine 
during this trial, further instructions are provided in the protocol- specific MOP.  
6.1.2. Formulation, Packaging, and Labeling  
ChAd3 -EBO -Z  
ChAd3 -EBO -Z is presented as a clear, sterile liquid suspension filled in stoppered glass vials. 
The nominal titer for the vaccine is 2 x 1011 vp/mL.   Vials have a fill volume of approximately 
1.2 mL. 1.0 mL is to be administered  IM. 
The study product will be labeled according to manufacturer specifications and include the statement “Caution: New Drug – Limited by Federal Law to Investigational Use”.  
MVA- BN® -Filo 
MVA- BN® -Filo is a milky, light yellow suspension with no visible extraneous particles and 
contains trometamol (tris -hydroxymethyl- amino methane) and sodium chloride as formulation 
buffers.   
The vaccine is supplied in a 2mL type I borosilicate glass vial closed with a sterile bromobutyl 
rubber stopper, crimped with an aluminum cap and covered with a polypropylene closure. The 
nominal titer for the vaccine is 2.0 x 108 Inf. U/m L. Vials are filled with an extra amount of 
vaccine (fill volume: 0.69 mL) to assure an extractable volume of 0.5mL.  
The study product will be labeled according to manufacturer specifications and include the 
statement “Caution: New Drug – Limited by Feder al Law to Investigational Use”.  
Placebo  
Placebo will be supplied as 0.9% Sodium Chloride Injection, USP which is a colorless, sterile, 
nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg. It contains no bacteriostatic, antimicrobial agent, or added buffer and is supplied only in single-dose containers. The placebo, 0.9% Sodium Chloride, contains no preservatives. The solution may contain hydrochloric acid and/or sodium hydroxide for pH 
adjustment (pH 5.3 [4.5 to 7.0]). 0.5 mL is to be administered IM.  
6.1.3. Product Storage and Stability  
ChAd3 -EBO -Z  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           54 
CONFIDENTIAL  
 ChAd3 -EBO -Z vaccine vials must be stored at -60°C to -90°C. If the vaccine cannot be 
administered immediately, it is recommended to administer the product within 6 hours after 
thawing.  
MVA- BN® -Filo 
MVA- BN®-Filo vaccine vials must be stored at -20°C to -80°C. If the vaccine cannot be 
administered immediately  it is recommended to administer the product within 4 hours after 
preparation in syringe .  
Placebo  
Placebo must be stored at 20ºC to 25ºC (68°F to 77ºF) [See USP Controlled Room Temperature; 
excursions between 15°C and 30°C (59°F and 86°F) are permitted]. S ee protocol -specific MOP 
for further instructions.  
The temperature of the storage unit must be recorded manually daily (excluding non- business 
days and holidays as applicable), continuously monitored and recorded during the duration of this trial per the p articipating VTEU site’s standard operating procedures (SOPs) , and 
documentation will be maintained. If the temperature fluctuates outside of the required range, the affected study product(s) must be quarantined at the correct storage temperature and labeled as ‘Do Not Use’ (until further notice). The research pharmacist must alert the site principal investigator and study coordinator, if the temperature fluctuates outside of the required range. In the event the temperature fluctuates outside of the require d range, the affected study product(s) 
must not be administered. The site principal investigator or responsible person should immediately contact the DMID Product Support Team at DMIDProductSupportTeam@niaid.nih.gov for further instructions before any additional study vaccinations are administered. Based on the information collected, DMID and/or the manufacturer will determine whether the affected study product(s) can be used. If it cannot be 
used, the site will receive specific instructions on how to return the affected study product(s) to 
the DMID CMS or destroy it on site. Additional instructions for quarantine are provided in the protocol- specific MOP.  
6.2. Dosage, Preparation and Administration of Study Intervention/  
Investigational Product 
See the protocol-specific MOP for detailed information on the preparation, labeling, storage, and administration of study product for each treatment arm. Study product preparation will be performed by the participating VTEU site’s research pharmacist on the same day of stu dy 
vaccine administration.  
Visually inspect the study product upon receipt and prior to use. If the study product(s) appear(s) 
to have been damaged, contaminated or discolored, contain visible particulate matter or if there 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           55 
CONFIDENTIAL  
 are any concerns regarding its i ntegrity, do NOT use the affected study product(s). The affected 
study product(s) must be quarantined as per storage requirements and labeled as ‘Do Not Use’ 
(until further notice). The site principal investigator or responsible person should immediately 
contact the DMID Product Support Team at DMIDProductSupportTeam@niaid.nih.gov and DMID Clinical Project Manager for further instructions before any additional study vaccinations are administered . Based on the information collected, DMID and/or the manufacturer will 
determine whether the affected study product(s) can be used. If it cannot be used, the site will 
receive specific instructions on how to return the affected study product(s) to the DMID CMS or 
destroy it on site. If the study product is unusable, study personnel will use another vial from the 
study supply. Replacement vials may be requested by contacting DMID. Additional instructions for quarantine and DMID contact information are provided in the protocol- specific MOP.  
ChAd3 -EBO -Z  
The study product will be prepared for administration by thawing at room temperature. Once the last ice crystals have disappeared within the thawed vials, the vial should be gently shaken to 
homogenize the suspension. After thawing, the drug product should appear as transparent and 
without precipitates. The vaccine should be visually inspected for any foreign particulate matter prior to administration. In case foreign particulate matter is visable, the vaccine mu st not be used. 
The final dose of vaccine will be  2 x 10
11 vp.  
MVA- BN® -Filo 
The study product will be prepared for administration by thawing at room temperature. To ensure homogeneity, upon thawing the vial should be swirled gently ( not shaken)  for at least 30 
seconds. After thawing, the drug product should appear as a clear to milky colored suspension. The liquid vaccine should be visually inspected for any foreign particulate matter prior to 
administration. In case foreign particulate matter is visible, the vaccine must not be used. The 
final dose of vaccine will be 1 x 10
8 IU. 
The vaccines will be administered via intramuscular injection into the deltoid. For the second 
injection, subjects will receive study vaccine or placebo via intramuscula r injection into the 
opposite arm that was used for the first injection (left or right deltoid). Study product 
administration will be performed by an unblinded study personnel member who is credentialed to administer vaccines and may also participate in dose preparation, but will not be involved in study- related assessments or have subject contact for data collection following study vaccine 
administration.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           56 
CONFIDENTIAL  
 6.3. Modification of Study Intervention/Investigational Product for a 
Subject 
There will be no dose modifications. If a subject’s second  vaccin ation is deferred, attempts will 
be made to reschedule the vaccination  to occur within the acceptable protocol-specified window 
for that visit .   
6.4. Accountability Procedures for the Study Intervention/Investigational 
Product(s) 
After receipt of the study vaccine, the site principal investigator is responsible for its distribution 
and disposition, and has ultimate responsibility for study vaccine accou ntability. As this is a 
blinded study, the site PI will delegate this responsibility to the unblinded site pharmacist. Study 
vaccine records must be maintained and document logs of receipt, accountability, and storage 
temperature conditions.  The study product accountability records and dispensing logs will also 
capture vial numbers, including final vial number, date of study vaccine preparation/ administration, time of study vaccine preparation, time study vaccine is drawn into the syringe, and amount of st udy vaccine withdrawn for administration. Time of study vaccine administration 
to the subject will be captured on the appropriate data collection form. All study  vaccine, 
whether administered or not, must be documented on the appropriate study product accountability record or dispensing log. The sponsor's monitoring staff will verify the 
participating VTEU site’s study product accountability records and dispensing logs per the site monitoring plan.  
Used and unused vaccines , will be retained until monitored and released for disposition as 
applicable. Filled, un -used syringes will be retained until monitored and released for disposition 
as applicable. Final disposition of the unused vaccine will be determined by DMID and communicated to the participating VTEU site by the DMID Clinical Project Manager.  
6.5. Assessment of Subject Compliance with Investigational Product  
Study products will be administered to subjects via intramuscular injection by study personnel 
according to subject treatment assignment and as described in Section 6.2 Thus, subject 
compliance is not anticipated to be an issue. Deviations from the dose schedule may only occur as described in Section 6.3 . 
6.6. Concomitant Medications/Treatments  
Administration of any medications, therapies, or vaccines will be recorded on the appropriate data collection form. Concomitant medications will include all current medications and medications taken within 60 days prior to signing the informed consent form through 
approximately 28 days after the second  study vaccination or early termination (if prior to 28 days 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           57 
CONFIDENTIAL  
 after the second study vaccination), whichever occurs first. Assessment of study eligibility will 
include a review of all permitted and prohibited medications per the Subject Inclusion and 
Exclusion Criteria (see Section 5 ). Medications reported in the electronic case report form 
(eCRF) are limited to those taken within 30 days prior to study vaccination through 
approximately 28 days after the second  study vaccination. Prescription and over- the-counter 
drugs will be included as well as herbals, vitamins, and supplements. In addition, receipt of non-study vaccines will be solicited through approximately 28 days after the second study 
vaccination, and reported in the eC RF. 
Use of new medication should prompt evaluation for the occurrence of an AE or worsening of a pre-existing medical condition.  
Medications that might interfere with the evaluation of the investigational product(s) should not be used from time of study vaccination through 28 days post the second  vaccination unless 
clinically indicated as part of the subject’s health care. Medications in this category include the prohibited medications per the Subject Exclusion Criteria (see Section 5.2 ). In addition, the site 
principal investigator or appropriate sub -investigator may identify other medications that should 
not be used due to a risk to subject safety o r assessment of reactogenicity and immunogenicity. 
Use of medications as prophylaxis prior to study vaccination is prohibited. There are no known drug-vaccine interactions with the study vaccine and subjects are not being asked to discontinue current medic ations not listed in the exclusion criteria. In  the event medical conditions dictate 
use of medications, subjects are encouraged to obtain adequate care, comply with the course of therapy as prescribed by their physician and inform the site as soon as practicable. Details of all medications taken during the medication reportin g period for this study (date, indication, brand 
or generic name) will be recorded.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           58 
CONFIDENTIAL  
 7 STUDY SCHEDULE  
Complete study schedule details listed by type of visit are described below. Refer also to 
Sections 4 and 8, and Appendix A : Schedule of Study Procedures and Evaluations. 
7.1. Screening  
Day < - 29 to - 1, Visit 00  
Potential subjects will be screened for eligibility within 28 days prior to the administration of study vaccination. The following activities will be performed at screening  and may be done all at 
one visit or split into separate visits : 
• Subjects will be provided with a description of this trial (purpose and study procedures) and asked  to read and sign the informed consent form. The informed consent form will be signed 
prior to performing any study procedures, including any screening procedures. 
• Demographic information will be obtained by interview of subjects. 
• History of military service prior to 1991 or after January 2003. Subjects will be interview ed 
for possible receipt of vaccinia -based vaccine. 
• Eligibility criteria will be reviewed with subjects.  
• Complete medical history will be obtained by interview of subjects.    
• History of all concomitant medications taken within 60 days prior to signing the informed consent form will be reviewed with subjects. Medications reported in the eCRF are limited to 
those taken within 30 days prior to study vaccination. Assessment of stud y eligibility will 
include a review of all permitted and prohibited medications per the Subject Inclusion and 
Exclusion Criteria (see Section 5 ).  
• Vital signs, including oral temperature, pulse, and blood pressure, will be obtained. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
• Height and weight will be collected. BMI will be calculated to determine eligibility.   
• An ECG will be performed  and read to determine eligibility . 
• A physical examination will be performed to include the following organs and organ 
systems: general appearance, skin, head and neck, lungs, heart, liver, spleen, extremities, 
musculoskeletal, lymph nodes, and nervous system by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site principal investigator or sub-investigator.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           59 
CONFIDENTIAL  
 • A serum pregnancy test will be performed on all females of childbearing potential and must 
be negative. 
• Venous blood will be collected for scree ning laboratory tests (refer to Section 8.2.1) to be run 
at the local clinical laboratory.  
• Urine will be collected for screening urinalysis (dipstick) for urine protein and urine toxicology screen for opiates. Values must meet the eligibility criteria (see Section 5 ) prior to 
randomization. 
7.2. Enrollment/ Baseline  
Day 1, Visit 1 
Sixty subjects who meet all inclusion and no exclusion criteria will be administered study 
product. The following procedures will o ccur for all Treatment Arms:  
• Subject’s willingness to participate will be reconfirmed and documented in the subject’s study records prior to performing any further study procedures, including administration of the study vaccine. 
• Eligibility criteria, inclu ding results of all clinical screening laboratory evaluations, will be 
reviewed with subjects prior to study vaccination to ensure continued eligibility. 
• Complete medical history and any updates obtained by interview of subjects since the 
screening visit w ill be reviewed with subjects prior to study vaccination to ensure continued 
eligibility.  
• All concomitant medications will be reviewed with subjects prior to study vaccination for accuracy and completeness. Any new concomitant medications (including non- study 
vaccines) taken since the screening visit will be reviewed with subjects and assessed for 
continued eligibility prior to study vaccination. Medications reported in the eCRF are limited to those taken within 30 days prior to study vaccination. 
• Vital sig ns, including oral temperature, pulse, and blood pressure, will be obtained to ensure 
eligibility. Vital signs assessed on Day 1 prior to the first study vaccination will be considered as baseline. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
• A targeted physical examination may be performed prior to study vaccination, if indicated based on review of complete medical history and any updates obtained by interview of subjects since the screen ing visit, by a study clinician licensed to make medical diagnoses 
and listed on the Form FDA 1572 as the site principal investigator or sub- investigator.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           60 
CONFIDENTIAL  
 • A urine pregnancy test will be performed within 24 hours prior to study vaccination on all 
females of childbearing potential. Results must be negative and known prior to 
randomization and study vaccination. 
• Subjects will be enrolled in AdvantageEDCSM and assigned randomly to a treatment arm 
prior to study vaccination. 
• Venous blood will be collected prior to the study vaccination for safety labs (refer to Section 
8.2.1).  
• Venous blood will be collected prior to the study vaccination for high resolution HLA typing 
for Class 1 (A, B, and C locus) testing.   
• Venous blood will be collected prior to the study vaccination for future use assays.  
• Venous blood will be collected prior to the study vaccination for baseline immunogenicity and exploratory assays (please refer to  Appendix A :  Schedule of Study Procedures and 
Evaluations for type of assays requiring collection).  
• Pre-administration reactogenicity assessments will be performed prior to study vaccination to 
establish a baseline. Subjects will then receive study vaccine or placebo via intramuscular injection into the left or right deltoid. The time of administration will be recorded on the 
appropriate data collection form. Subjects will be observed for at least 30 min utes after study 
vaccination. Post -administration reactogenicity assessments will be performed. Any 
AE/SAEs /MAAEs will be recorded on the appropriate data collection form prior to discharge 
from the clinic.   
• Subjects will be provided with a memory aid and other study- related materials to record daily 
oral temperature, solicited site and systemic AEs, unsolicited AEs, and concomitant medications. Subjects will be encouraged to take their oral temperature around the same time each day. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes 
prior to taking oral temperature. Subjects will be instructed on how to use their memory aid and how to measure and record AEs prior to discharge from the clinic. Subjects will be 
instructed to notify the study center if they develop any severe reactions after study 
vaccination. If the site principal investigator or appropriate sub -investigator deems the 
reaction severe enough, further instructions will be given to the subject on the proper course of action, including a return to the clinic for immediate evaluation if appropriate.  
7.3. Follow -up 
7.3.1. Follow- up Visits, post first vaccination  
Day 2  (V02), 3 (V03), 4 (V04) and 6 (V05) 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           61 
CONFIDENTIAL  
 Follow- up visits are scheduled in reference to study vaccination date as indicated for each visit 
window. All subjects will return on D2, 3, 4, 6 post the first vaccination. The following 
assessments will occur:  
• Interim medical history will be obtained by interview of subjects to ensure continued 
eligibility. Any changes since the previous clinic visit or contact will be noted at each clinic 
visit.  
• All concomitant medications (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data collection form at each clinic visit. Any new 
concomitant medications taken since the last clinic visit or phone contact will be reviewed 
with subjects and assessed for continued eligibility. 
• A targeted physical examination may be performed, if indicated based on review of complete 
medical history and any updates obtained by interview of subjects, by a study clinician 
licensed to make medical diagnoses and listed on the Form FDA 1572 as the site principal 
investigator or sub- investigator. 
• Venous blood will be collected for immunogenicity and exploratory ass ays (please refer to 
Appendix A :  Schedule of Study Procedures and Evaluations for type of assays requiring 
collection).  
• All AEs , SAEs  and MAA Es will be collected and recorded on the appropriate data collection 
form at each clinic visit.  
• Memory aid information will be reviewed with subjects at each clinic visit.  
7.3.2. Follow- up Vaccination Visit  
Day 8  +2 (post first vaccination), Visit 06  
All subjects w ill return for vaccination on D8. The following assessments will occur. 
• Eligibility criteria will be reviewed with subjects prior to study vaccination to ensure continued eligibility (see Section  5.3). 
• Interim medical history will be obtained by interview of subjects to ensure continued eligibility. Any changes since the previous clinic visit or contact will be noted at each clinic visit.  
• All concomitant medications (including solicitation for receipt of any non-study vaccines) 
will be recorded on the appropriate data collection form at each clinic visit. Any new concomitant medications taken since the last clinic visit or phone contact will be  reviewed 
with subjects and assessed for continued eligibility. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           62 
CONFIDENTIAL  
 • Vital signs, including oral temperature, pulse, and blood pressure, will be obtained to ensure 
continued eligibility. Subjects must not eat or drink anything hot or cold, or smoke within 10 
minutes prior to taking oral temperature.  
• A targeted physical examination may be performed prior to study vaccination, if indicated 
based on review of complete medical history and any updates obtained by interview of 
subjects since the screening visit, by a study clinician listed on the Form FDA 1572. 
• A urine pregnancy test will be performed within 24 hours prior to study vaccination on all 
females of childbearing potential. Results must be negative and known prior to randomization and study vaccination. 
• Veno us blood will be collected prior to the study vaccination for safety labs  (See Section 
8.2.1).  
• Venous blood will be collected prior to the study vaccination for future use assays.  
• Venous blood will be collected prior to the study vaccination for immunogenicity and exploratory assays (please refer to Appendix A : Schedule of Study Procedures and 
Evaluations for type of assays requiring collection).  
• Pre-administration reactogenicity assessments will be performed prior to study vaccination to 
establish a baseline. Subjects will then receive study vaccine or placebo via intramuscular 
injection into the opposite arm that was used for the first injection ( left or right deltoid ). The 
time of administration will be recorded on the appropriate data collection form. Subjects will 
be observed for at least 30 minutes after study vaccination. Post- administration 
reactogenicity assessments will be performed. Any A Es, SAEs , and MAAEs  will be recorded 
on the appropriate data collection form prior to discharge from the clinic.   
• Subjects will be provided with a memory aid and other study- related materials to record daily 
oral temperature, solicited site and systemic A Es, unsolicited AEs, and concomitant 
medications. Subjects will be encouraged to take their oral temperature around the same time each day. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes 
prior to taking oral temperature. Su bjects will be instructed on how to use their memory aid 
and how to measure and record AEs prior to discharge from the clinic. Subjects will be 
instructed to notify the study center if they develop any severe reactions after study vaccination. If the site principal investigator or appropriate sub -investigator deems the 
reaction severe enough, further instructions will be given to the subject on the proper course 
of action, including a return to the clinic for immediate evaluation if appropriate.  
• All AEs , SAEs , and MAAEs  will be collected and recorded on the appropriate data collection 
form at each clinic visit.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           63 
CONFIDENTIAL  
 7.3.3. Follow-up Visits, post second vaccination 
Day 2  (V07), 8 +1  (V08), 15 +2/-1 (V09), 22 +/ -1 (V10), 29 +/ -2 (V11) post second vaccination  
Follow- up visits are scheduled in reference to study vaccination date as indicated for each visit 
window. All subjects will return on D2, 8, 15, 22 and 29 post the second vaccination. The 
following assessments will occur:  
• Interim medical history will be obtained by interview of subjects to ensure continued eligibility. Any changes since the previous clinic visit or contact will be noted at each clinic visit.  
• All concomitant medications (including solicitation for receipt of any non-study vaccines) 
will be recorded on the appropriate data collection form at each clinic visit. Any new concomitant medications taken since the last clinic visit or phone contact will be reviewed with subjects and assessed for continued eligibility. 
• A targeted physical examination may be performed, if indicated based on review of complete 
medical history and any updates obtained by interview of subjects, by a study clinician listed on the Form FDA. 
• Venous blood will be collected for immunogenicity and exploratory assays (please refer to Appendix A  – Schedule of Study Procedures and Evaluations  for type of assays requiring 
collection).  
• Venous blood wil l be collected for safety labs only on Day 8 (+1), 22 (+/-1), and 29 (+/-2) 
post second vaccination  (See Section 8.2.1).  
• Venous blood will be collected for future use assays on Day 8 (+1), 15 (+ 2/-1), and 29 (+/- 2) 
post second vaccination  (See Section 8.2.1).  
• All AEs , SAEs , and MAAEs  will be collected and recorded on the appropriate data collection 
form at each clinic visit.  
• Memory aid information will be reviewed with s ubjects on Day 2 and 8 post second 
vaccination. 
7.3.4. Follow- up Phone Call s 
Day 76 +/ -7 (V12), Day 106 +/-7 (V13) post first vaccination  
Follow- up visits are scheduled in reference to study vaccination date as indicated for each visit 
window. All subjects will be called at approximately D76 and 106 post the first vaccination. The following assessments will occur:  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           64 
CONFIDENTIAL  
 • Interim medical history will be reviewed to ensure continued eligibility. Any changes since 
the previous clinic visit or contact will be noted at the phone call. 
• All SAEs  and MAA Es will be collected and recorded on the appropriate data collection form 
at the phone call. 
7.4. Final Study Visit  
Day 182 +/ -14 post first vaccination, Visit 14  
Final visits are scheduled in reference to study vaccination date as indicated for each visit window. All subjects will return on D182 post the first vaccination for a final study visit. The 
following assessments will occur:  
• Interim medical history will be obtained by interview of subjects. Any changes since the 
previous clinic visit or contact will be noted.  
• A targeted physical examination may be performed, if indicated based on review of complete medical history and any updates obtained by interview of subjects, by a study clinician listed on the Form FDA 1572. 
• Venous blood will be collected for future use assays.  
• All SAEs  and MAA Es will be collected and recorded on the appropriate data collection form.  
7.5. Early Termination Visit (if needed)  
The following activities will be performed on all subjects at the early termination visit on subjects who withdraw, or are withdrawn or terminated from this trial:  
• Interim medical history will be obtained by interview of subjects and any changes since the 
previous clinic visit or contact will be noted (if indicated).  
• Memory aid information will be reviewed with subjects (if within 7 days post study 
vaccination). 
• All concomitant medications (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data collection form (if prior to 28 days  post second  study 
vaccination). 
• All AE , SAEs , and MAAEs  will be recorded on the appropriate data collection form. AEs 
will be recorded if prior to 28 days post second  study vaccination. AEs will be limited to 
SAEs  and MAA Es, if after 28 days post first study vaccination. 
• A targeted physical examination may be performed, if indicated based on review of interim medical history, by a study clinician licensed listed on the Form FDA 1572. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           65 
CONFIDENTIAL  
 • Vital signs, including oral temperature, pulse, and blood pressure maybe obtained .Subjects 
must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral 
temperature.  
• Venous blood will be collected for safety laboratory evaluations ( see Section 8.2.1) and 
performed by the local (clinical) laboratory (if within 28 days post second  study vaccination). 
• Venous blood will be collected for immunogenicity and exploratory assays.  
7.6. Unscheduled Visit (if needed)  
Unscheduled visits may occur at any time during this trial. Any of the following activities may be performed: 
• Interim medical history will be obtained by interview of subjects and any changes since the 
previous clinic visit or contact will b e noted (if indicated). 
• Memory aid information will be reviewed with subjects (if within 7 days post study vaccination). 
• All concomitant medications (including solicitation for receipt of any non -study vaccines) 
will be recorded on the appropriate data col lection form (if prior to 28 days post second  study 
vaccination). 
• All AE , SAEs , and MAAEs  will be recorded on the appropriate data collection form. AEs 
will be recorded if prior to 28 days post last study vaccination. AEs will be limited to SAEs and AEs if after 28 days post first study vaccination. 
• A targeted physical examination may be performed, if indicated based on review of interim 
medical history, by a study clinician licensed listed on the Form FDA 1572. 
• Vital signs, including oral temperature, pulse, and blood pressure, may be obtained. Subjects 
must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
• Venous blood will be collected for safety laboratory evaluations ( see Section 8.2.1) and 
performed by the local (clinical) laboratory (if within 28 days post second  study vaccination). 
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           66 
CONFIDENTIAL  
 8 STUDY PROCEDURES/EVALUATIONS  
8.1. Clinical Evaluations 
Complete medical history will be obtain ed by interview of subjects at the screening visit and will 
be reviewed and/or updated on Day 1 prior to study vaccination. Subjects will be queried 
regarding a history of significant medical disorders of the head, eyes, ears, nose, throat, mouth, 
cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, urologic system, nervous system, blood, lymph nodes, endocrine system, musculoskeletal system, skin, and genital/reproductive tract. A history of any allergies, cancer, immunodeficiency , psychiatric 
illness, substance abuse, and autoimmune disease will be solicited. At follow -up visits after study 
vaccination, an interim medical history will be obtained by interview of subjects noting any changes since the previous clinic visit or contact. The interim medical history should include an assessment for new medical conditions.  
Medication history (concomitant medications) will include a review of all current medications and medications taken within 60 days prior to signing the informed consent form through 
approximately 28 days after the second  study vaccination or early termination (if prior to 28 days 
after the second study vaccination), whichever occurs first. Medications reported in the eCRF are 
limited to those taken within 30 days prior to study vaccination through approximately 28 days 
after the second study vaccination. Prescription and over- the-counter drugs will be included as 
well as herbals, vitamins, and supplements. In addition, receipt of non-study vaccines will be solicited through approximately 28 days after the second  study vaccination, and reported in the 
eCRF. Use of new medication should prompt evaluation for the occurrence of any AE. Assessment of eligibility will include a review of all permitted and prohibited medications per the Subject Inclusion and Exclusion Criteria (see Sections 5.1 and 5.2). In addition, the site 
principal investigator or appropriate sub -investigator may identify o ther medications that should 
not be used due to a risk to subject safety or assessment of reactogenicity and immunogenicity. 
A full physical examination will be performed on all subjects at the screening visit. This exam 
will include the following organs a nd organ systems: skin, head and neck, lungs, heart, liver, 
spleen, extremities, musculoskeletal, lymph nodes and nervous system, by a study clinician 
licensed to make medical diagnoses and listed on the Form FDA 1572 as the site principal investigator or sub-investigator. Vital signs (oral temperature, pulse, and blood pressure) will be 
collected at the screening visit. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature. Height and weight will b e collected at the 
screening visit.  BMI will be calculated, and eligibility determined. 
A single, 12- lead ECG will be performed at screening and will be read locally. 
Electrocardiograms will only be repeated during the study if clinically indicated based on signs and symptoms (per the investigator’s judgment). During the collection of ECGs, subjects should 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           67 
CONFIDENTIAL  
 be in supine position in a quiet setting without distractions. Subjects should rest (while sitting 
comfortably) for at least 5  minutes before ECG collection and should refrain from talking or 
moving arms or legs.  
On Day 1 prior to the study vaccination and at follow-up visits after the study vaccination, a 
targeted physical examination may be performed, if indicated based on the subject’s interim 
medical history, by a study clinician licensed to make medical diagnoses and listed on the Form 
FDA 1572 as the site principal investigator or sub-investigator.  
On Day 1 and all vaccination vis its, vital signs (oral temperature, pulse, and blood pressure) will 
be collected prior to study vaccination. A urine pregnancy test will be performed within 24 hours 
prior to study vaccination on all females of childbearing potential. Pre -administration 
reactogenicity assessments will be performed prior to each study vaccination to establish 
baseline, then the study vaccination will be given. Subjects will be observed in the clinic for at 
least 30 minutes after each study vaccination. The study vaccination site will be examined, post-administration reactogenicity assessments will be performed and any AE , SAEs  and MA AEs 
will be recorded on the appropriate data collection form prior to discharge from the clinic. All subjects will receive and complete a subject  memory aid from the time of study vaccination 
through 7 days after study vaccination. Subject memory aids will be reviewed with the subjects for adverse events, (solicited local and systemic AEs and unsolicited AEs) approximately at day 8 after each vacci nation. 
Reactogenicity assessments will include an assessment of solicited adverse events occurring from the time of study vaccination through 7 days after study vaccination. These include local reactions such as pain, tenderness, erythema (redness), indur ation (hardness/swelling), pruritic 
(itching) and bruising as well as systemic AEs such as fever, feverishness (chills, shivering, 
sweating), fatigue (tiredness), malaise (general unwell feeling), myalgia (body aches/muscular 
pain), nausea, loss of appetit e and headache. 
8.2. Laboratory Evaluations  
8.2.1. Clinical Laboratory Evaluations 
Serum βHCG pregnancy tests will be done at the screening visit for all females of childbearing 
potential and processed locally by the site laboratory . A urine pregnancy test will be performed 
within 24 hours prior to  each study vaccination on all females of childbearing potential. Urine 
will be collected in a sterile urine cup for processing by research staff using a CLIA waived urine pregnancy test kit. Results must be negative and known prior to randomization on Day 1 and prior to administration of study vaccination on Day 8. 
Venous blood will be collected prior to the first study vaccination on day 1 for  high resolution 
HLA typing for Class 1 (A, B, and C locus) testing.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           68 
CONFIDENTIAL  
 Clinical screening laboratory tests will be performed at the screening visit and processed by the 
local (clinical) laboratory. Parameters to be evaluated to confirm trial eligibility as per Section 
5.1, include the following: 
• Hematology: WBC, Hgb, platelet count, ANC, and HgbA1c.   
• Biochemistry: Creatinine, sodium, potassium, albumin, total protein and ALT. BUN will be 
done if creatinine is above the normal range.    
• Serum serology testing for HIV – 1/2 antibody, HCV antibody, and HBsAg. 
• Clotting : PT and PTT 
• Urinalysis will be done to test for urine protein via dipstick in the clinic. Clean -catch, mid -
stream, urine specimen will be collected in a ster ile urine cup.  
• Urine test for opiates:  A clean -catch, mid -stream urine specimen will be collected in a sterile 
urine cup and transported to the clinical laboratory for processing and examination.  
Clinical safety labs will be performed on Day 1, 8, 15, 29, and 36. If they are abnormal, they will 
be assessed, documented, reported, and followed   until the lab returns to the subject’s baseline value or has  stabili zed. Clinical safety laboratory param eters to be evaluated will include WBC, 
Hgb, platelet count, ANC, sodium, potassium, c reatinine and ALT. BUN will be obtained only if 
creatinine is above the normal range. These evaluations will be performed by the local (clinical) laboratory. Venous blood will be collected for safety laboratory evaluations and performed by the local (clinical) laboratory for early termination visits or unscheduled visits occurring within 28 days post second  study vaccination. 
8.2.2. Special Assays or Procedures 
Immunogenicity testing will include the following  (post first vaccination) :   
• Humoral responses by ELISA and ADCC at D ay 1, 8, 15, 22, 29 and 36. 
• Humoral response by EBOV GP Neut at Day 1, 8 and 15.   
• Cell-mediated immunity assays (EBOV GP T cell response) at Day 1, 8 , 15, 22, and 36. 
• Cell-mediated immunity assays (ChAd3 vector T cell response)  at Day 1, 8, 15, 22 and 36. 
• Plasmablasts (5), BCR repertoire analysis (11), CD8  tetramer staining and activation marker 
analysis at Day 1, 8 and 15. 
• Cytokine/chemokine measurement at  Day 1, 2, 3, 4, 6, 8, 9, and 15. 
• Transcriptomics/Gene expression  PBMCs at Day 1, 2, 3, 4, 6, 8, 9 and 15. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           69 
CONFIDENTIAL  
 • Characterization of antigen -specific BCR as measured by yeast display on day 36.  
Venous blood samples will also be collected for future use. 8 mL will be collected on Day 1, 8, 
15, 22 and 36 post first vaccination. 42 ml will be collected on Day 182 post first vaccination. Collection of future use samples is a condition of participation in this study .  
The volume (ml) of venous blood to be collected for immunogenicity assays and future research 
is presented in Table 2.  
Table 2: Blood Volumes (ml)  
Study Visit (V)  0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
 
US  
ED Study Day (from 
Vaccine 1)  < -29 1 2 3 4 6 8 9 15 22 29 36 76 106 182 
Screening Lab  14.2                 
Clinical Safety 
Evaluations   6.5     6.5  6.5  6.5 6.5    6.5^ 6.5^ 
High Resolution 
HLA tying for Class 
1 (A, B, C locus)   6.0                
Humoral response – 
 ELISA (Op 2)   
10.0     
10.0  
10.0 10.0 10.0 10.0     
10.0
^ Humoral response –  
ADCC (Op 7)            
Humoral Response, 
EBOV GP Neut 
Antibody (Op7a)               
EBOV GP T cell 
responses (Op 3)   
24.0     
24.0  
24.0 24.0  
24.0      
ChAd3 vector T cell 
responses (Op 4)              
Plasmablasts (Op 5, 
11)  32.0     32.0  32.0         
Cd8 Tetramer 
Staining (Op 9)   
8.0     
8.0  
8.0        
8.0* Activation Marker 
Analysis  
(Op 10)               
Exploratory 
cytokine/ 
chemokine  
(Op 6)   5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0         
Transcriptomics 
PMBCs (Op 8)   16.0 16.0 16.0 16.0 16.0 16.0 16.0 16.0         
Yeast Display             16.0      
Future Use   8.0     8.0  8.0 8.0  8.0   42.0   
Total per visit   14.2 115.5 21.0 21.0 21.0 21.0 109.5 21.0 109.5 42.0 16.5 64.5 0.0 0.0 42.0 6.5 14.5-
24.5 
Running Total  14.2 129.7 150.7 171.7 192.7 213.7 323.2 344.2 453.7 495.7 512.2 576.7 576.7 576.7 618.7 N/A N/A 
^ to be collected if visit occurs prior to or on Day 36 (post first vaccination)  
* to be collected if visit occurs prior to or on Day 15 (post first vaccination)  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           70 
CONFIDENTIAL  
 8.2.3. Specimen Preparation, Handling, and Shipping  
8.2.3.1. Instructions for Specimen Preparation, Handling, and Storage  
Instructions for specimen preparation, handling, and storage are included in the protocol- specific 
MOP as appropriate. 
8.2.3.2. Specimen Shipment  
Specimen shipment will occur when all specimens are available following all applicable 
International Air Transport Association (IATA) requirements and according to the specifics for storage temperature and documentation as detailed in the local (clinical) laboratory manual and 
protocol- specific MOP as appropriate.  
All specimens for clinical screening and safety laboratory evaluations will be transported from the participating VTEU site to the local (clinical) laboratory.  
Specimens for cellular assays will be transported from the participating VTEU site to the local 
(research) laboratory.  
Specimens for antibody assays will be shipped from the participating VTEU site to the Clinical 
Materials Services. 
Further instructions for specimen shipment are included in the local (clinical) laboratory manual 
and protocol- specific MOP, as appropriate.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           71 
CONFIDENTIAL  
 9 ASSESSMENT OF SAFETY  
9.1. Specification of Safety Parameters  
Safety will be assessed by the occurrence of:  
1. Serious adverse events, and MAAE s occurring from the time of study vaccination through 
approximately 6 months after the first study vaccination. 
2. Solicited Adverse Events – reactogenicity events occurring from the time of study 
vaccination through 7 days after each study vaccination: 
a) Local AEs including pain, tenderness, erythema (redness), induration 
(hardness/swelling), ecchymosis ( bruising ) and pruritis (itching).  
b) Systemic AEs including fever, feverishness (chills, shivering, sweating), fatigue 
(tiredness), malaise (general unwell feeling), myalgia (body aches/muscular pain), 
nausea, loss of appetite  and headache. 
3. Clinical safety laboratory  adverse events occurring from the time of study vaccination 
through approximately 28 days after the second vaccination. Parameters to be evaluated include WBC, Hgb, platelet count, ANC, sodium, potassium, Creatinine, BUN (BUN will be obtained only if creatinine is above the normal range), and ALT.   
4. Unsolicited Adverse Events – study vaccine -related non-serious adverse events occurring 
from the time of study vaccination through approximately 28 days after the second  study 
vaccination. 
9.2. Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
9.2.1. Adverse Events  
Adverse Event:  ICH E6 defines an AE as any untoward medical occurrence in a patient or 
clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study treatment. FDA defines an AE as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of medicinal (investigational) 
product. The occurrence of an AE may come to the attention of study personnel during study 
visits and interviews of a study recipient presenting for medical care, or upon review by a study monitor.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           72 
CONFIDENTIAL  
 AEs, including solicited local (injection site) and systemic (subjective and quantitative) 
reactions , will be captured on the appropriate data collection form and eCRF. Information to be 
collected for unsolicited non- serious AEs includes event description, date  of onset, assessment of 
severity , relationship to study product and alternate etiology  (assessed only by those with the 
training and authority to make a diagnosis and listed on the Form FDA 1572 as an investigator), 
date of resolution , seriousness and outcome. AEs occurring during the trial collection and 
reporting period will be documented appropriately regardless of relationship. AEs will be 
followed through resolution. 
Any medical condition that is present at the time that the subjec t is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre- existing medical 
condition increases, it should be recorded as an AE. All AEs must be graded for severity and relationship to study product (see definitions). Adverse 
events characterized as intermitten t require documentation of onset and duration of each episode. 
The start and stop date of each reported AE will be recorded on the appropriate data collection 
form and eCRF.  
Severity of Event:  AEs will be assessed by the investigator using a protocol-defined grading 
system  (toxicity table included as an appendix) . For events not included in the protocol-defined 
grading system, the following guidelines will be used to quantify severity: 
• Mild (Grade 1) : Events require minimal or no treatment and do not interfere with the 
subject’s daily activities.  
• Moderate (Grade 2) : Events result in a low level of inconvenience or concern with 
therapeutic measures. Moderate events may cause some interference with functioning and 
daily activities.  
• Severe (Grade 3) : Events interrupt the subject’s daily activities and may require systemic 
drug therapy or other treatment. Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
intermittent require documentation of onset and duration of each episode. 
Relationship to Study Products: The assessment of the relationship of an AE to  the 
administration of study product is made only by those with the training and authority to make a 
diagnosis and listed on the Form FDA 1572 as an investigator based on all available information 
at the time of the completion of the eCRF.  Whether the AE i s related or not,  is not a factor in 
determining what is or is not reported in this trial. If there is any doubt as to whether a clinical observation is an AE, the event should be reported.   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           73 
CONFIDENTIAL  
 In a clinical trial, the study product must always be suspect. To help assess, the following 
guidelines are used. 
• Related  – There is a reasonable possibility that the study product caused the adverse event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the event. 
Medically Attended Adverse Event (MAAE):  For each unsolicited AE experienced, the 
subject will be asked if he/she had received medical attention, defined as hospitalization, an 
emergency room visit, or an otherwise unscheduled visit to or from medical personnel for any reason. AEs characterized by such unscheduled medical care will be designated as MAAEs. 
9.2.2. Reactogenici ty 
Reactogenicity events are AEs that are common and known to occur following administration of 
this type of study vaccine. The following Toxicity Grading Scales will be used to grade solicited 
local (injection site) and systemic (subjective and quantitati ve) reactions: 
Table 3:  Local (Injection Site) Reactogenicity Grading  
Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain – experienced 
without touching the injection site (spontaneous discomfort) Subject is aware of pain, 
but it does not interfere 
with daily activity,  and 
no pain medication is taken  Subject is aware of pain; 
there is interference with daily activity  or it 
requires repeated use of a non-narcotic pain relieve r 
for >24 hours  Subject is aware of pain, and it prevents daily 
activity
 or requires any use 
of a prescription medication.  
Tenderness – hurts only 
when injection site is touched or the arm is moved The area immediately 
surrounding the injection site hurts only when 
touched or with arm 
motion, and it does not 
interfere with daily activity  The area immediately surrounding the injection site hurts when touched or with arm motion, and it 
interferes with daily 
activity  The area immediately surrounding the injection 
site hurts when touched or 
with arm motion, and it 
prevents daily activity  
Erythema (Redness)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Induration 
(Hardness/Swelling)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           74 
CONFIDENTIAL  
 Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Ecchymosis (Bruising)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Pruritus (Itching)  Does not interfere with 
daily activi ty Interferes with daily 
activi ty Prevents daily activity 
* Will also be measured in mm but size will not be used as halting criteria.  
Ecchymosis (bruising), erythema (redness) and induration (hardness)/swelling as analyzed by 
measurement will be graded as follows:  
Table 4: Local (Injection Site) Reactogenicity Measurements 
Local (Injection Site) Reaction  Small  Medium  Large  
Ecchymosis (Bruising)*  <20 mm  20 mm – 50 mm  >50 mm  
Erythema (Redness)*  <20 mm  20 mm – 50 mm  >50 mm  
Induration (Hardness)/Swelling*  <20 mm  20 mm – 50 mm  >50 mm  
* Will not be used as halting criteria.  
Table 5: Subjective Systemic Reactogenicity Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Feverishness (chills/shivering/sweating)  noticeable but does not 
interfere with daily activity   interferes with daily activity  Significant interference, 
prevents daily activity  
Malaise (General Unwell 
Feeling)  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference, prevents daily activity  
Fatigue (Tiredness)  noticeable but does not 
interfere with daily 
activity   interferes with daily activity  Significant interference, prevents daily activity  
Myalgia (Body Aches/Muscular Pain)*  noticeable but does not 
interfere with daily activity   interferes with daily activity  Significant interference, prevents daily a ctivity  
Headache  noticeable but does not interfere with daily activity  Any use of pain reliever or interferes  with daily 
activity  Significant interference, 
prevents daily activity, or 
requires any u se of a 
prescription medication  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           75 
CONFIDENTIAL  
 Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Nausea  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant interference, prevents daily activity  
Loss of Appetite  noticeable but does not 
interfere with daily 
activity   interferes with daily 
activity  Significant inte rference, 
prevents daily activity  
* Not at injection site.  
Oral temperature# will be graded as follows: 
Table 6: Quantitative Systemic Reactogenicity Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral† 37.8°C – 38.4°C  
100.00°F – 101.1°F  38.5°C – 38.9°C  
101.2°F – 102.0°F  >38.9°C  
>102.0°F  
# Oral temperature assessed on Day 1 prior to study vaccination will be considered as baseline.  
* A fever can be considered not related to the study product if an alternative etiology can be documented.  
† Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
Pulse and blood pressure# will be graded as follows: 
Table 7:  Blood Pressure and Pulse Grading  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute  45-46 40 – 44 <40 
Tachycardia - beats per minute  106 – 130 131 – 155 >155  
Hypotension (systolic) mmHg  80 – 84 75 – 79 <75 
Hypotension (diastolic) mmHg  50 – 54 45 – 49 <45 
Hypertension (systolic) mmHg  151 – 155 156 – 160 >160  
Hypertension (diastolic) mmHg  96 – 100 101 – 105 >105  
# Pulse and blood pressure assessed on Day 1 prior to study vaccination will be considered as baseline.  
Clinical safety laboratory results will be graded as follows:  
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           76 
CONFIDENTIAL  
 Table 8: Clinical Safety Laboratory Adverse Event Grading (Hematology) 
Hematology  Clinical 
Laboratory 
Reference Range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
WBC K/mcL  (Decrease , 18 to <21 years ) 4.5 – 13.0 2.5 – 4.4 1.5 – 2.4 <1.5 
WBC K/mcL  (Decrease, ≥ 21 years)  4.5 – 11.0 2.5 – 4.4 1.5 – 2.4 <1.5 
WBC K/mcL  (Increase 18 to <21 years)  4.5 – 13.0 13.1 – 15.0 15.1 – 20.0 >20.0  
WBC K/mcL  (Increase > 21 years)  4.5 – 11.0 11.1 – 15.0 15.1 – 20.0 >20.0  
Hgb g/dL (Decrease) (Female)  11.7 – 15.7 10.1 – 11.6 8.5 – 10 <8.5 
Hgb g/dL (Decrease) (Male)  13.3 – 17.7 11.0 – 13.2 9.5 – 10.9 <9.5 
Platelet count K/mcL  (Decrease)  135 - 466 125 – 134 100 – 124 <100  
Platelet count K/mcL  (Increase)  135 - 466 467 - 517 518 – 750 >750  
Absolute Neutrophil Count, K/mcL* (18 to < 21 
years)  1.80 – 8.00 1.5-<1.8 1.0-<1.5 <1.0 
Absolute Neutrophil Count, K/mc L* (≥ 21 years)  1.80 – 7.70 1.5-<1.8 1.0-<1.5 <1.0 
Absolute Neutrophil Count, K/mcL  - Benign 
Ethnic Neutropenia*  > 0.8 0.6 – 0.7 0.4 -- 0.5 < 0.4  
*  ANC for subjects that are of African American and Middle Eastern descent may have values as low as 0.8 x K/mcL .  
Subjects of this descent must have an ANC ≥ 0.8 K/mcL  to be eligible to participate in the study if all other study criteria 
are met.   
Table 9: Clinical Safety Laboratory Adverse Event Grading (Chemistry)  
Chemistry  Clinical Laboratory 
Reference Range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
ALT unit /L (Increase)  ≤ 49 50 - 123 124 - 245 > 245 
Creatinine mg/dL (Increase - Female)  0.50–0.80 0.81–1.70 1.71–2.00 >2.00  
Creatinine mg/dL (Increase - Male)  0.60–1.10 1.11 –1.70 1.71  2.00 >2.00  
Sodium, low, mmol/L  136 – 145 130 - 135 123-129 <123  
Sodium, high, mmol/L  136 - 145 146 - 150 151-157 >157  
Potassium, high, mmol/L  3.5 – 5.1 5.2 - 6.0 6.1-6.5 >6.5 
Potassium, low,  mmol/L  3.5 – 5.1 3.0 - 3.4 2.5-2.9 <2.5 
Blood Urea Nitrogen (BUN) mg/dL  9.00 – 23.00  24 - 26 27-31 >31 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           77 
CONFIDENTIAL  
 9.2.3. Serious Adverse Events 
Serious Adverse Event (SAE): An adverse event or suspected adverse reaction is considered 
“serious” if, in the view of either the investigator or sponsor, it results in any of the following 
outcomes:  
• Death,  
• a life -threatening adverse event1,  
• inpatient hospitalization or prolongation of existing hospitalization,  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or  
• a congenital anomaly/birth defect.   
• Important medical events that may not res ult in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical judgment 
they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
1  Life-threatening adverse event.  An adverse event is considered “life -threatening” if, in the view of either the 
site principal investigator or sponsor, its occurrence places the patient or subject at immediate risk of death. It 
does not include an adverse event, had it occurred in a more severe form, might have caused death.  
SAEs will be:  
• Assessed for severity and relationship to  study product and alternate etiology. 
• Recorded on the appropriate SAE data collection form and eCRF.  
• Followed through resolution. 
• Reviewed and evaluated by an Independent Safety Monitor (ISM) (as deemed necessary), the SMC (periodic review unless related), DMID, and the IRB.  
9.2.4. Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  
The site principal investigator or appropriate sub -investigator is responsible for recording all 
AE/SAEs /MAAEs  that are observed or reported during this trial, regardless of the relationship to 
study product. AE/SAEs /MAAEs , abnormal laboratory test values, or abnormal clinical findings 
will be collected, assessed, documented, reported, and followedappropriately. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           78 
CONFIDENTIAL  
 For baseline laboratory results that are abnormal according to the local laboratory reference 
range and fall within Grade 1 toxicity table range, these will not be considered laboratory 
adverse event (AE) and will thus not be graded. However, if baseline clinical labs fall within 
Grade 1 range, then a laboratory AE is reported only if the value changes such that it falls into 
Grade 2 or higher when subsequent safety laboratory testing is done. 
9.3. Reporting Procedures 
Solicited local and systemic AEs  will be documented and reported from the time of study 
vaccination through 7 days after each study vaccination. 
Clinical safety laboratory adverse events will be documented and reported on Day s 1, 8, 15, 29 
and 36. The clinical safety laboratory tests will be collected  prior to vaccination on Days 1 and 8. 
Additional safety labs will be collected and AEs reported if the subject returns to the clinic for 
re-evaluation of laboratory adverse events until resolution.  
Unsolicited non- serious AEs will be documented and reported from the time of study vaccination 
through approximately 28 days after the second  study vaccination. 
SAEs (including lab values that meet SAE criteria), MAAEs  will be documented and reported 
from the time of study vaccination through approximately 6 months after the first study 
vaccination. 
At any time after completion of this trial, if the site principal investigator or appropriate sub -
investigator becomes aware of an SAE that is suspected to be related to study product, the site 
principal investigator or appropriate sub -investigator will report the event to the DMID 
Pharmacovigilance Group. 
9.3.1. Serious Adverse Events 
SAEs will be followed until resolution even if this extends beyond the study-reporting period. 
Resolution of an AE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
Any AE th at meets a protocol -defined serious criterion must be submitted immediately (within 
24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the 
following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Man agement Support (CROMS)  
6500 Rock Spring Dr. Suite 650 
Bethesda, MD 20817, USA 
SAE Hot Line: 1 -800- 537-9979 (US) or 1-301-897-1709 (outside US) 
SAE FAX Number: 1 -800-275-7619 (US) or 1-301-897-1710 (outside US) 
SAE Email Address: PVG@dmidcroms.com  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           79 
CONFIDENTIAL  
 In addit ion to the SAE form, select SAE data fields must also be entered into the DCC system 
(for example : Advantage EDC) . Please see the protocol -specific MOP for details regarding this 
procedure.  
Other supporting documentation of the event may be requested by t he DMID Pharmacovigilance 
Group and should be provided as soon as possible.  
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group. The DMID Medical Monitor and DMID Clinical Project Manager will be notified of the SAE by the DMID Pharmacovigilance Group. The DMID Medical Monitor will review and assess the SAE for regulatory reporting and 
potential impact on study subject safety and protocol conduct. 
At any time after completion of the study, if the site principal investigator or appropriate sub-
investigator becomes aware of an SAE that is suspected to be related to study product, the site 
principal investigator or appropriate sub- investigator will rep ort the event to the DMID 
Pharmacovigilance Group. 
9.3.2. Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the investigator, DMID, the Investigational New Drug (IND) 
sponsor, will report any suspected adverse reactio n that is both serious and unexpected. DMID 
will report an adverse event as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the drug and the adverse event. DMID will notify FDA and all 
participating investiga tors (i.e., all investigators to whom the sponsor is providing drug under its 
IND(s) or under any principal investigator’s IND(s)) in an IND safety report of potential serious 
risks from clinical trials or any other source, as soon as possible, but in no case later than 15 
calendar days after the sponsor determines that the information qualifies for reporting as 
specified in 21 CFR Part 312.32. DMID will also notify FDA of any unexpected fatal or life-
threatening suspected adverse reaction as soon as possi ble, but in no case later than 7 calendar 
days after the sponsor’s initial receipt of the information. Relevant follow up information to an 
IND safety report will be submitted as soon as the information is available. Upon request from FDA, DMID will submit  to FDA any additional data or information that the agency deems 
necessary, as soon as possible, but in no case later than 15 calendar days after receiving the 
request.  
All serious events designated as “not related” to study product(s), will be reported to the FDA at 
least annually in a summary format. 
9.3.3. Other Adverse Events  
N/A 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           80 
CONFIDENTIAL  
 9.3.4. Reporting of Pregnancy  
Pregnancies occurring in study subjects will be reported via AdvantageEDCSM on the Pregnancy 
Report form. With the subject’s permission, all protocol-required venous blood samples will be 
obtained and the subject will continue to be followed for safety for the duration of this trial. 
Efforts will be made to follow all pregnancies reported during the course of this trial to pregnancy outcome pending the subject’s permission. 
9.4. Type a nd Duration of Follow -up of Subjects after Adverse Events 
AEs will be collected, assessed, and followed through resolution from the time of study vaccination through approximately 28 days after the second  study vaccination. 
SAEs  and MAAEs  will be collected, assessed, and followed from the time of study vaccination 
through resolution even if this extends beyond the trial-reporting period (approximately 6 months 
after the first study vaccination). 
Resolution of an AE/SAE /MAAE  is defined as the return to pretreatment status or stabilization 
of the condition with the expectation that it will remain chronic.  
Follow-up procedures, evaluations, and outcomes will be recorded on the appropriate data 
collection form.  
9.5. Halting Rules 
Further enrollment and study vaccinations will be halted for SMC review/recommendation if any 
of the following are reported:  
• Any subject experiences a study product- related SAE from the time of the study product 
administration through the subject’s last study visit.  
• Any subject experiences laryngospasm, bronchospasm, or anaphylaxis within 1 day after administration of study product that is considered related to study product. 
• Two or more subjects experience generalized urticaria (defined as occurring at more t han two 
body parts) within 3 days after administration of study product that is considered related to study product. 
• Two or more subjects experience the same grade 3 unsolicited AE (in the same MedDRA High Level Term) after administration of study product that is considered related to study 
product and not resolved or improved to lower grade within 2 days. 
• Two or more subjects experience the same grade 3 laboratory adverse event that is considered related to study product. 
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           81 
CONFIDENTIAL  
 This trial will also be halted fo r SMC  review/recommendation if, within 7 days after 
administration of any study vaccination, any of the following occurs: 
• Two or more subjects experience the same grade 3 solicited local adverse event that is 
considered related to study product and not resolved or decreased to lower grade within 2 
days. 
• Two or more subjects experience the same grade 3 solicited systemic adverse event that is considered related to study product and not resolved or decreased to lower grade within 2 
days. 
Grading scales for solicited local (application site) and systemic (subjective and quantitative) AEs are included in Section 9.2.2. 
Grading scales for clinical safety laboratory adverse events are included in Section 9.2.2. 
If any of the halting rules are met following any subject receipt of any study vaccination, then 
this trial will not continue with the remaining enrollments or study vaccinations without a review by and recommendation from the SMC to proceed. 
DMI D retains the authority to suspend additional enrollment and study interventions/ 
administration of study product during the entire trial, as applicable. 
9.6. Safety Oversight (ISM plus SMC ) 
9.6.1. Independent Safety Monitor (ISM)  
An ISM is a physician with relevant expertise whose primary responsibility is to provide to 
DMID an independent safety assessment in a timely fashion. Participation is for the duration of 
the DMID study and is a voluntary position that does not receive payment. The ISM must meet 
the requirements of the NIAID conflict of interest policy.    
The ISM:  
• Is in close proximity to the study site and has the authority and ability to readily access study participant records in real time.  
• May be a member of the participating institution’s staff but preferably be from a different organizational group within the institution. 
• Should not be in a direct supervisory relationship with the investigator.  
• Should have no direct involvement in the conduct of the study. 
 
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           82 
CONFIDENTIAL  
 The ISM will:  
• Sign a Conflict of Interest (COI ) certification at the time they are asked to participate and 
provide updates to this information as needed. 
• Receive reports of Serious Adverse Events (SAEs) from the site investigator and will be 
notified by email when DMID is notified of the SAE. 
• Evaluate the SAE and report their clinical assessment to DMID, through DMID -CROMS 
SOCS in a timely manner using the attached report form and email the report to DMID -
CROMS SOCS.   
• Communicate with the investigator at the participating site as needed.  
• Review additional safety related events at the request of DMID.  
• Provide additional information to DMID and/or the SMC by teleconference as requested.  
9.6.2. Safety Monitoring Committee (SMC) 
This clinical study will utilize an SMC, which is an independent group of experts that advises 
DMID. The primary responsibility of the SMC is to monitor subject safety. The SMC is external 
to the DMID and comprises at least 3 voting members. The SMC will consist of members with appropriate Phase 1 study expertise to contribute t o the interpretation of the data from this trial. 
Its activities will be delineated in a SMC charter that will describe the membership, responsibilities, and the scope and frequency of data reviews. The SMC will operate on a conflict- free basis independent ly of the study team. The DMID or the SMC may convene ad hoc 
meetings of the SMC according to protocol criteria or if there are concerns that arise during the study. 
The SMC will review the safety data at the following milestones:  
• Organizational meeting (p rior to start of the study)   
• Scheduled Data Review meetings  
• An SMC Ad Hoc meeting will be convened when a halting rule is met, or at the request of 
the investigator and/or DMID if there are safety concerns during the course of the study.  
• Final review meeting, to be conducted 6 to 8 months after clinical database lock to review the 
cumulative unblinded safety data for the study. The data will be provided in a standard 
summary format. The SMC may be asked to provide recommendations in response to questions posed by the DMID. 
The SMC will operate under the rules of a D MID -approved charter that will be written at the 
organizational meeting of the SMC. At this time, each data element that the SMC needs to assess 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           83 
CONFIDENTIAL  
 will be clearly defined. Procedures for SMC reviews/meetings will be defined in the charter. The 
SMC will revie w applicable data to include, but not limited to, study progress and participant, 
clinical, safety, and reactogenicity data. Reports may include enrollment and demographic information, medical history, concomitant medications, physical assessments, clinica l laboratory 
values, dosing compliance, and solicited and unsolicited AE/SAEs /MAAEs . Additional data may 
be requested by the SMC, and interim statistical reports may be generated as deemed necessary and appropriate by DMID. The SMC may receive data in aggregate and presented by cohort. The 
SMC may also be provided with expected and observed rates of the expected AEs in an 
unblinded fashion, and may request the treatment assignment be unblinded for an individual subject if required for safety assessment. The  SMC will review grouped and unblinded data in 
the closed session only. The SMC will meet and review this data at scheduled time points or ad hoc as needed during this trial as defined in the SMC charter. As an outcome of each 
review/meeting, the SMC will make a recommendation as to the advisability of proceeding with 
study vaccinations (as applicable), and to continue, modify, or terminate this trial.  
DMID or the SMC chair may convene the SMC on an ad hoc basis according to protocol criteria 
or if there ar e immediate concerns regarding observations during the course of this trial. The 
DMID Medical Monitor is empowered to stop enrollment and study vaccinations if adverse events that meet the halting criteria are reported. The DMID Medical Monitor and the ISM  (as 
deemed necessary) will be responsible for reviewing SAEs in real time. The SMC will review SAEs on a regular basis and ad hoc during this trial. 
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           84 
CONFIDENTIAL  
 10 CLINICAL MONITORING  
10.1. Site Monitoring Plan 
Site monitoring is conducted to ensure that the human subjects’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is 
conducted in accordance with the protocol, protocol- specific MOP and applicable sponsor 
standard operating procedures. DMID, the sponsoring agency, or its designee will conduct site-monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals a s defined by DMID and may be made more 
frequently as directed by DMID. Monitoring visits will include, but are not limited to, review of regulatory files, accountability records, eCRFs, informed consent forms, medical and laboratory reports, and protocol a nd GCP compliance. Site monitors will have access to each participating 
VTEU site, study personnel, and all study documentation according to the DMID-approved site monitoring plan. Study monitors will meet with site principal investigators to discuss any 
problems and actions to be taken and document visit findings and discussions. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           85 
CONFIDENTIAL  
 11 STATISTICAL CONSIDERATIONS  
This is a Phase 1, randomized, double-blind trial of 60 males and non-pregnant females, 18-45 
years old, inclusive, who are in good health, meet all eligibility criteria, and do not meet any exclusion criteria. This trial is designed to assess the safety, reactogenicity and immunogenicity 
of a Zaire ebolavirus  (ChAd3 -EBO-Z) vaccine for the prevention of Ebola virus disease. ChAd3-
EBO- Z will be administere d intramuscularly on Day 1 followed by either placebo (Group 1), 
ChAd3 -EBO -Z (Group 2), or MVA- BN® -Filo (Group 3) at Day 8. The clinical trial includes an 
exploratory systems biology component to identify changes in gene expression that are 
associated wit h adaptive humoral and/or cellular immune responses.  
11.1. Study Hypotheses 
This Phase I study is not designed to test a formal null hypothesis. The sample size for this study was selected to obtain preliminary estimates of vaccine safety and immunogenicity. The clinical trial includes an exploratory systems biology component to identify changes in gene expression, and cytokines that are associated with adaptive humoral and/or cellular immune responses. These 
systems biology results are expected to generate hypot heses to be verified in future studies.  
11.2. Sample Size Considerations  
See Section 11.1 and Section 4. 
11.3. Planned Interim Analyses  
11.3.1. Interim Safety Review  
An interim safety re view may include enrollment and demographic information, medical history, 
concomitant medications, physical assessments, dosing compliance, protocol adherence, clinical 
laboratory values, and solicited and unsolicited AEs. Additional data may be requested by the SMC, and interim safety reports may be generated as deemed necessary and appropriate by DMID. The SMC will receive data in aggregate. The SMC may request the treatment group be unblinded for an individual subject if required for safety assessment. T he SMC will review 
grouped and unblinded data in the closed session only. The SMC will meet and review this data at scheduled time points or ad hoc as needed during this trial as defined in the SMC charter. As an outcome of each review/meeting, the SMC will make a recommendation as to the advisability of proceeding with study vaccinations (as applicable), and to continue, modify, or terminate this trial. 
11.3.2. Interim Immunogenicity Review  
An interim immunogenicity review is not planned.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           86 
CONFIDENTIAL  
 11.4. Final Analysis Plan  
The final CSR will be completed after the last subject’s last visit is completed, and the final 
clinical database including all long -term safety follow -up data is cleaned, monitored and locked. 
The primary CSR will include results for all primary and secon dary endpoint data as well as 
exploratory EBOV GP pseudovirion neutralization assay data . Additional results for  exploratory 
endpoint data will be  included as one or more addenda to the primary CSR. A formal Statistical 
Analysis Plan that specifies all planned analyses will be developed and finalized prior to the final 
clinical database lock.  
11.4.1. Analysis Populations  
The Safety Analysis population includes all subjects who received at least one study vaccination. 
The intent- to-treat (ITT) population includes all subjects who received at least one study 
vaccination and contributed both pre- and at least one post -study vaccination blood samples for 
immunogenicity testing for which valid results were reported. Subjects will be analyzed 
according to the study group to which they were randomized. 
The per protocol (PP) population includes all subjects in the ITT subset with the following 
exclusions: 
• Data from all available visits for subjects found to be ineligible at baseline.  
• Data from all visits sub sequent to major protocol deviations, such as: 
o Second study vaccination not received, 
o Receipt of non- study licensed live vaccine within 30 days prior to or after each study 
vaccination, 
o Receipt of non- study licensed inactivated vaccine within 14 days prior  to or after 
each study vaccination, 
o Receipt of oral or parenteral (including intraarticular) corticosteroids of any dose 
within 30 days prior to study vaccination. 
o Receipt of high- dose inhaled corticosteroids within 30 days prior to study 
vaccination.   
o Receipt of chronic (defined as more than 14 days) immunosuppressants or other 
immune modifying drugs within 6 months of receipt of study vaccine. 
• Data from any visit that occurs outside the pre-defined protocol window. 
• In the case of mis -randomization, subjects will be analyzed according to the study product 
actually received.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           87 
CONFIDENTIAL  
 11.4.2. Safety Data 
Safety data will be summarized for the Safety Analysis Population. Pre -second vaccination, 
Study Groups 1, 2, 3 will be analyzed jointly as one study group as all three groups received the 
same vaccine at Day 1.  
Solicited AEs will be summarized by severity for each day after each study vaccination (Days 1  
through 7 days post-vaccination) and as the maximum severity over all days after each vaccination. The maximum severity o f local and systemic reactions will be determined for each 
subject and summarized by study group following each vaccination (as well as post any 
vaccination) and the resulting number, percentage (observed rate) of subjects and associated 
exact 95% confidence interval (CI) will be summarized by severity grade (none, mild, moderate, 
severe) and symptom. Summaries will also be provided for any systemic symptoms, for any local 
symptoms, and for any systematic or local symptoms. 
Vaccine- related unsolicited AEs from the first study vaccination through 28 days post second 
vaccination will be coded by Medical Dictionary for Regulatory Activities (MedDRA ®) for 
preferred term  and  system organ class (SOC). These AEs will be summarized as number and 
percentage of subjects reporting at least one event in each MedDRA ®
 preferred term and SOC, 
cross tabulated by severity grade (none, mild, moderate, severe). Additionally, the number, 
percentage (observed rate) and exact two -sided 95% CI for subjects reporting a related 
unsolicited AE overall, by SOC, and by preferred term will be summarized by study group. 
Clinical safety laboratory AEs from the time of first study vaccination through ap proximately 28 
days after the second vaccination  will be summarized by severity grade (none, mild, moderate, 
severe)  for each laboratory visit. In addition, the maximum severity over all post-vaccination 
visits will be summarized  by study visit and by seve rity grade (none, mild, moderate, severe) 
using percentages and exact two -sided 95% CIs. 
The number of SAEs and vaccine -related Medically Attended Adverse Events (MAAEs) through 
6 months post first vaccination  will be reported by detailed listings showing the event 
description, preferred term and SOC, relevant dates (study vaccinations and AEs), severity, 
vaccine -relatedness, and outcome for each event.  
11.4.3. Secondary Immunogenicity Data 
Immunogenicity data summaries and analysis will be presented for both the ITT and PP 
populations. Pre-second vaccination, Study Groups 1, 2, 3 will be analyzed jointly as one study group as all three study groups received the same vaccine at Day 1. 
Seroconversion for anti -EBOV GP ELISA (defined as EBOV GP ELISA titer > 50 if baseline 
(Day 1) titer ≤ 50 or fold rise of > 4- fold as compared to baseline if the baseline titer > 50), will 
be summarized for each post -vaccination study visit day (Day 8, 15, 22, 29 and 36) and study 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           88 
CONFIDENTIAL  
 group using percentages and exact two -sided 95% CIs. Per -visit seroconversion percentages and 
CIs will be visualized across study visit days using time trend plots.  
Anti-EBOV GP ELISA titer at Day 1, 8, 15, 22, 29 and 36 will be summarized by calculating the 
geometric mean (GMT) titer and corresponding 95% CIs for each study group and day by 
transforming individual titer results to a logarithmic scale, assuming asymptotic normality 
conditions were satisfied on this scale, computing the mean and 95% CI then converting back to the original scale. Per -visit GMTs and CIs will be visualized across study visit days using time 
trend plots.  
Change in Anti-EBOV GP ELISA titer at Day 8, 15, 22, 29 and 36 compared to baseline (Day 1) will be summarized by calculating the geometric mean fold rise (GMFR) and corresponding 95% 
CIs for each study group and day by dividing the post-vaccination titer for each subject by the respective pre- vaccination titer, transforming ratios to a logarithmic scale, assuming asymptotic 
normality conditions were sat isfied on this scale, computing the mean and 95% CI then 
converting back to the original scale. Per- visit GMFR and CIs will be visualized across post -
vaccination study visit days using time trend plots. 
11.4.4. Exploratory Data Analyses 
Pre-second vaccination, Study Groups 1, 2, 3 will be analyzed jointly as one study group as all 
three study groups received the same vaccine at Day 1.  
GMT of neutralizing antibodies to EBOV GP at Day 8 and 15 and GMFR in titer on Day 8 and 
15 compared to baseline (Day 1) and associated 95% C Is will be calculated and summarized as 
described in  Section 11.4.3. Significant differences in neutralizing antibodies to EBOV GP or 
Anti-EBOV GP ELISA titer  between study groups for each post-second vaccination time points 
will be evaluated using a two- sided Welch's T-test using an individual alpha of 0.05. Differences 
in Anti -EBOV GP ELISA -based seroconversion at post-second vaccination time points will be 
assessed using a two -sided Fishers’ exact test using an individual alpha of 0.05. 
Baseline fold changes for
35 percentage of killed cells36 percentage of activated CD4+ and CD8+ 
T cells37, cytokine concentrations38, percentage of EBOV GP -specific cytokine secreting CD4+ 
and CD8+ T cells expression one, two, or multiple makers39, percentage of EBOV GP -specific 
CD4+ and CD8+ T cells40, percentage of ChAd3 -specific cytokine secreting CD4+ and CD8+ T 
cells41, percentage o f CD19+CD27+CD38+ plasmablasts will be summarized using minimum, 
Q1, median, Q3, maximum, and 95% CI of the median. The 95% CI of the median fold change 
from baseline will be determined by using the bootstrap method and visualized using time trend plots. T o identify features that show a differential response from baseline, a two -sided Wilcoxon 
signed-rank test will be carried out for each study group using an individual alpha of 0.05. Significant differences in fold changes between study groups for post- second vaccination time 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           89 
CONFIDENTIAL  
 points will be evaluated using a two-sided Wilcoxon rank-sum test using an individual alpha of 
0.05.  
For the transcriptomics exploratory analysis, RNA -Seq data will be pre -processed by removing 
adapters and low- quality reads and mappi ng sequences to the latest human reference genome 
using splice- aware alignment software such as HISAT235. Gene expression quantification will be 
carried out by using the Subread software36 using the latest Ensembl37 gene model annotations as 
a reference. Systematic differences in sequence coverage between samples will be accounted for 
using the TMM method38 as implemented in the edgeR39 R package. Principal component 
analysis, non- metric multidimensional scaling, and hierarchical clustering analysis will be used 
to identify potential global outliers and systematic batch effect. Negative binomial models as 
implemented in edgeR39 will be used to identify genes for each study group and post-vaccination 
day that we re differentially expressed  (DE) compared to pre- vaccination as well as genes that 
were DE between study groups. If the analysis reveals a systematic batch effect that is not 
associated with study group, it will be accounted for by adding a batch blocking factor as part of the negative binomial models.  To control for testing multiple genes, the false -discovery rate 
(FDR) based on the Benjamini-Hochberg procedure
40 as implemented in the p.adjust  R function 
will be applied. Genes with a FDR -value < 0.05 and a fold change of greater or equal to 1.5- fold 
(up or down regulation) will be deemed to be significantly DE. Depending on observed treatment effects, t his fold change cut off may be revised. The pvclust
41 R package will be applied to 
identify co- expressed DE gene clusters and cluster time trends will be visualized . Pathway 
enrichment analysis based on the latest MSigDB42 and KEGG43 databases as well as Blood 
Transcription Modules44  accounting for gene length bias will be carried out using the 
implementation provided by the goseq45 R package. Pathway maps color-coded by treatment 
effect will be provided for significantly enriched KEGG pathways. Regularized c anonical 
correlation analysis and regularized linear regression analysis as implemented in the mixOmics46 
and glmnet47 R packages, respectively will be utilized to identify gene expression changes that 
are associated with adaptive humoral and/or cellular immune response endpoints.  In both cases, 
cross- validation will be used to select optimal models.  
Please see the separate document “Statistical Analysis Plan ” for additional information on 
exploratory endpoint analyses.  
11.4.5. Missing Values and Outliers  
All attempts will be made to collect all data per protocol.  
As missing data are expected to be minimal, no imputation will be performed for missing values. Any data point that appears to be erroneous or inexplicable based on clinical judgment will be investigated as a possible outlier. If data points are identified as outliers, sensitivity analyses will be performed to examine the impact of including or excluding the outliers. Any substantive 
differences in these analyses will be reported. 
  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           90 
CONFIDENTIAL  
 For the transcriptomics endpoint, extreme data points will be identified by inspecting global 
patterns in the data. Experimental meta -data will be examined to see whether the outlying pattern 
can be attributed to experimental error such as sample mislabeling. Excluded outliers will be 
documented in the CSR. Due to the complexity, no sensitivity analysis will be carried out for the transcriptomics endpoints.  
Please see the separate document “Statist ical Analysis Plan”  for additional information.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           91 
CONFIDENTIAL  
 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records in compliance 
with ICH E6, Section 4.9 and regulatory and institutional requ irements for the protection of 
confidentiality of subjects. Each site will permit authorized representatives of the DMID, its designees, and appropriate regulatory agencies to examine (and when required by applicable law, to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of 
the study safety and progress. These representatives will be permitted access to all source data and source documents, which include, but are not limited to, hospital records, clinical and of fice 
charts, laboratory notes, memoranda, subjects’ memory aid or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiche s, photographic negatives, microfilm 
or magnetic media, x -rays, and subject files and records kept at the pharmacy, at the laboratories, 
and medico- technical departments involved in the clinical trial.  
Interview of subjects is sufficient for obtaining med ical history.  
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           92 
CONFIDENTIAL  
 13 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, each participating site and its 
subcontractors are responsible for conducting routine quality assurance (QA) and quality control 
(QC) activities to internally monitor study progress and protocol compliance. The site principal 
investigator will provide direct access to all study -related sites, source data/data collection forms, 
and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local 
and regulatory authorities. The site principal investigator will ensure all study personnel are appropriately trained and applicable documentations are maintained on site. 
The DCC will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data 
anomalies will be communicated to the participating site(s) for clarification and resolution.  
DMID- designated clinical monitors will verify that the clinical trial is conducted and data are 
generated, documented (recorded), and reported in compliance with the protocol, ICH/GCP guidelines, and the applicable regulatory requirements. Clinical monitor ing reports will be 
submitted to DMID.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           93 
CONFIDENTIAL  
 14 ETHICS/PROTECTION OF HUMAN SUBJECTS  
14.1. Ethical Standard  
The site principal investigator (PI) will ensure that this trial is conducted in full conformity with 
principles of the Belmont Report: Ethical Principles and Guidelines for the Protection  of Human 
Subjects of Research ( National Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research [April 18, 1979] ) and codified in 45 CFR 46, 21 CFR 50 and 21 CFR 
56, as applicable. The PI will also ensur e conformity with ICH E6 Good Clinical Practice, and 
applicable federal regulations, guidance, and guidelines for Good Clinical Practice and Clinical Trials with humans.  
14.2. Institutional Review Board  
The site principal investigator will obtain IRB approval for this protocol to be conducted at 
his/her research site(s), and send supporting documentation to the DMID before initiating recruitment of subjects. The investigator will submit applicable informatio n to the IRB/IEC on 
which it relies for the review, to conduct the review in accordance with 45 CFR 46, ICH E6 
GCP, and as applicable, 21 CFR 56 (Institutional Review Boards) and 21 CFR 50 (Protection of 
Human Subjects) , other federal, state, and local regulations. The  IRB/IEC must be registered 
with Office of Human Research Protection  [OHRP -only  or OHRP/FDA] as applicable to the 
research. DMID must receive the documentation that verifies IRB/IEC -approval for this 
protocol, associated informed consent documents, and upon request any recruitment material and 
handouts or surveys intended for the subjects, prior to the recruitment and enrollment of subjects.     
Any amendments to the protocol or consent materials will be app roved by the IRB/IEC before 
they are implemented. IRB/IEC review and approval will occur at least annually throughout the 
enrollment and follow -up of subjects, and may cease if annual review is no longer required by 
applicable regulations. The investigator  will notify the IRB/IEC of deviations from the protocol 
and reportable SAEs, as applicable to the IRB/IEC policy. 
Each institution engaged in this research will hold a current Federalwide Assurance (FWA) 
issued by the Office of Human Research Protection ( OHRP) for federally funded research.  
14.3. Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a trial and continuing throughout the individual’s trial participation. Before any study procedures are performed, informed consent will be obtained and documented. Subjects will receive a concise and focused presentation of key information about the clinical trial, verbally and with a 
written consent form. The explanation will be organized, and presented in lay terminology and 
language that facilitates understanding why one might or might not want to participate. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           94 
CONFIDENTIAL  
 An investigator or designee will describe the protocol to potential subjects face -to-face. The key 
information about the purpose of the study, the procedures and experimental aspects of the study, 
risks and discomforts, any expected benefits to the subject, and alternative treatment will be 
presented first to the subject.   
Subjects will also receive an explanation that the trial involves res earch, and a detailed summary 
of the proposed study procedures and study interventions/products. This will include aspects of 
the trial that are experimental, the probability for random assignment to treatment groups, any expected benefits, all possible ri sks (including a statement that the particular treatment or 
procedure may involve risks to the subject or to the embryo or fetus, if the subject is or may become pregnant, that are currently unforeseeable), the expected duration of the subject’s 
participation in the trial, alternative procedures that may be available and the important potential 
benefits and risks of these available alternative procedures.  
Subjects will be informed that they will be notified in a timely manner if information becomes availab le that may be relevant to their willingness to continue participation in the trial. Subjects 
will receive an explanation as to whether any compensation and any medical treatments are available if injury occurs, and, if so, what they consist of, or where f urther information may be 
obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject for participating in the trial, as well as any anticipated prorated payments, if any, to the subject for participating in the trial.  They will be informed of whom to contact (e.g., the investigator) for 
answers to any questions relating to the research project.  
Information will also include the foreseeable circumstances and/or reasons under which the 
subject’s participation in the trial may be terminated. The subjects will be informed that participation is voluntary and that they are free to withdraw from the study for any reason at any 
time without penalty or loss of benefits to which the subject is otherwise entitled.   
The extent of the confidentiality of the subjects’ records will be defined, and subjects will be 
informed that applicable data protection legislation will be followed. Subjects will be informed 
that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct 
access to the subject’s original medical records for verification of clinical trial procedures and/or data without violating the confidentiality of the subject, to the extent permitted by the applicable laws and regulations, and that, by signing a written informed consent form, the subject is authorizing such access.  
Subjects will be informed that records identifying the subject will be kept confidential, and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available and, if the results of the trial are published, the subject’s identity will remain confidential. Subjects will be informed whether private information collected from this research 
and/or specimens will be used for additional research, even if identifiers are removed.    
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           95 
CONFIDENTIAL  
 Subjects will be allowed sufficient time to consider participation in this research trial, and have 
the opportunity to discuss this trial with their family, friends or legally authorized representative, 
or think about it prior to agreeing to participate.  
Informed consent forms will be IRB -approved and subjects will be asked to read and review the 
consent form. Subjects must sign the informed consent form prior to starting any study procedures being done s pecifically for this trial.  
Once signed, a copy of the informed consent form will be given to the subject(s) for their 
records. The subject(s) may withdraw consent at any time throughout the course of the trial. The rights and welfare of the subject(s) will be protected by emphasizing to them that the quality of 
their medical care will not be adversely affected if they decline to participate in this study.  
Study personnel may employ recruitment efforts prior to obtaining study consent if a patient-
specific screening consent is on record or if the IRB has agreed that chart review is allowed 
without a fully executed screening consent. In cases where there is not a patient -specific 
screening consent on record, site C linical staff may pre- screen via chart review  and refer 
potential subjects to the Research staff. Research staff would obtain written consent per the 
standard informed consent process before conducting protocol- specific screening activities.  
New information will be communicated by the site principal investigator to subjects who consent 
to participate in this trial in accordance with IRB requirements. The informed consent document 
will be updated and subjects will be re- consented per IRB requirements, if necessary. Subjects 
will be given a copy of all informed consent forms that they sign.  
14.3.1. Informed Consent/Assent Process (in Case of a Minor)  
N/A 
14.4. Exclusion of Women, Minorities, and Children (Special Populations)  
This trial will be inclusive of all adults who meet the Subject Inclusion Criteria (see Section 5.1 ) 
and do not meet the Subject Exclusion Criteria (see Section 5.2), regardless of religion, sex, or 
ethnic background. Should the outcome of this trial be deemed acceptable, additional trials may be initiated including those in other populations. 
It is unknown if the vaccine poses any risks to an unborn child. Special populations, e.g., non-
English speakers, children, illiterate or non-writing individuals and vulnerable populations wil l 
not be enrolled in this study. The rationale for this is that this is an exploratory phase I study in 
healthy individuals that requires intensive visits and blood draws , which is most appropriately 
conducted in healthy, literate  adults.  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           96 
CONFIDENTIAL  
 14.5. Subject Confidentiality  
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and 
the sponsor(s) and their agents. This confidentiality includes documentation, investigation data, 
subject’s clinical information, and all other information generated during participation in the study. No information concerning the study or the data generated from the study will be released to any unauthorized third party without prior written approval of the DMID  and the subject. 
Subject confidentiality will be maintained when st udy results are published or discussed in 
conferences. The study monitor or other authorized representatives of the sponsor or 
governmental regulatory agencies may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the subjects in this study. The clinical study site will permit 
access to such records.  
All records will be kept locked and all computer entry and networking programs will be carried 
out with coded numbers only and with password protected systems. All non- clinical specimens, 
evaluation forms, reports, and other records that leave the site will be identified only by a coded number. 
To protect privacy, we have received a Certificate of Confidentiality. With this Certificate, the 
researchers cannot be forced to release information that may identify the research subject, even by a court subpoena, in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. The researchers will use the Certificate to resist any demands for information 
that would identify the subject, except as explained below. 
The Certificate cannot be used to resist a demand for information from personnel of the United 
States (US)  Government that is used for auditing or evaluation of federally funded projects, like 
this study, or for information that must be released in order to meet the requirements of the 
Federal Food and Drug Administration (FDA). 
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing 
information about themselves or their involvement in this research. If any person or agency 
obtains a written consent to receive research information, then the researchers may not use the 
Certificate to withhold that information.   
The Certificate of Confidentiality does not prevent the researchers from reporting without the subject’s consent, information that would identify the subject as a participant in the research 
project regarding matters that must be legally reported including : child and elder abuse, sexual 
abuse, or wanting to harm themselves or others.  
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           97 
CONFIDENTIAL  
 14.6. Study Discontinuation  
If the study is prematurely terminated by the sponsor, any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure appropriate therapy or follow -up for the subjects, as necessary. The investigator will provide a 
detailed written explanation of the termination to the IRB/IEC. If any subject’s private information will continue to be colle cted for this study, the IRB/IEC must approve a consent 
form with the study procedures, any risks and discomforts, and applicable elements, and the investigator or designee will re -consent the subjects as approved by the IRB/IEC. 
14.7. Costs, Subject Compensation, and Research Related Injuries  
There is no cost to subjects for the research tests, procedures, and study product while taking part 
in this trial.  Subjects may be compensated for their participation in this trial. Compensation will 
be in accordance with the local IRB’s policies and procedures, and subject to IRB approval. 
If it is determined by the site principal investigator that an injury occurred to a subject as a direct result of the tests or treatments that are done for this trial, then referrals to appropriate health care 
facilities will be provided to the subject. Study personnel will try to reduce, control, and treat any complications from this trial. Immediate medical treatment may be provided by the participating 
site. No financial compensation will be provided to the subject by the NIAID, NIH to the subject, 
or by the participating site for any injury suffered due to participation in this trial. 
14.8. Future Use of Stored Specimens and Data  
Residual samples are those that are left over after the study has been completed and are stored 
for possible use in future research studies. Future use samples are extra tube/s of blood collected 
and stored for possible use in future research studies. Retention of residual and future use 
samples and the potential for  use in future research studies will be a condition of study 
participation. Subjects who sign the informed consent form for the study are consent ing to allow 
the collection, storage and use of any residual samples  (serum or cells derived from vemous 
blood samples)  or future use samples for possible use in future research studies, such as examining additional immunological assessments or testing for antibodies against other viruses 
or bacteria. 
Future use samples will be collected at Day 1, 8, 15, 22, 36 and 182. It is anticipated that 
approximately two 0.5 mL aliquots of plasma and 2 aliquots of 5 x 10
6 cells from each extra 8 
mL venous blood sample will be available specifically for the purpose of future research at D 1, 
8, 15, 22 and 36. It is anticipated that approximately ten 0.5 mL aliquots of plasma and 8 aliquots of 5 x 10
6 cells from each extra 42 mL venous blood sample will be available specifically for the 
purpose of future research at D 182. Future use research studies may include, but are not limited 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           98 
CONFIDENTIAL  
 to non-traditional immune assay development, assessing innate immune factors and the ability of 
ebola vaccine-induced antibodies to cross- react with other viruses.  
Residual and future use samples will be encoded with a barcode label and unique tracking 
number to protect subject identity. Samples will be stored indefinitely at a DMID designated 
central storage facility. Residual samples may be shared for purposes other than per protocol 
analysis with investiga tors at participating VTEU sites and with investigators at other institutions 
once the clinical study report has been finalized. Future use research samples may be requested 
from DMID and shipped from the DMID CMS at any time.  
Residual and future use sampl es will not  be sold or used directly for production of any 
commercial product. Genetic tests may be performed on samples. There are no benefits to subjects in the collection, storage and subsequent use of their specimens for future research. Reports about future research done with subjects’ samples will NOT be kept in their health records.  
Subjects may withdraw consent for study participation at any time by notifying the study doctors 
or nurses in writing. However, any data from sample(s) collected prior t o the withdrawn consent 
will not be removed  including genomic data. There will be no further use of residual samples or 
collection and use of future use samples after consent has been withdrawn. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           99 
CONFIDENTIAL  
 15 DATA HANDLING AND RECORD KEEPING  
The investigator is responsible to ensure the accuracy, completeness, legibility, and timeliness of 
the data reported. All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black or blue permanent ink is required to ensure clarity of 
reproduced copies. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copies of the electronic CRF (eCRF) will be provided for use as source data collection forms  
and maintained for recording data for each subject enrolled in the study. Data reported in the eCRF derived from source data collection forms  should be consistent or the discrepancies should 
be explained. 
15.1. Data Management Responsibilities  
Data collection is the responsibility of the study personnel at the participating clinical study site under the supervision of the site principal investigator. During the study, the site principal 
investigator must maintain complete and accurate documentation for the study. 
The data coordinating center (DCC) for this study will be responsible for data management, 
quality review, analysis, and reporting of the study data. 
15.2. Data Capture Methods 
Clinical (including, but not limited to, AE/SAEs /MAAEs , concomitant medications, medical 
history, physical assessments, and clinical laboratory values ) and reactogenicity will be collected 
on data collection forms by study personnel then entered into eCRFs via a 21 CFR Part 11-
compliant internet data entry system provided by the study data coordinating center. The data 
system includes password protection and internal quality checks, such as automatic range checks, 
to identify data that appear inconsistent, incomplete, or inaccurate.   
15.3. Types of Data 
Data for this trial will include clinical, safety, and outcome measures (e.g., clinical laboratory values, reactogenicity, and immunogenicity data). 
15.4. Timing/Reports  
See Section 9.3 for further reporting details  
Interim statistical reports may be generated as deemed necessary and appropriate by DMID. Safety reports may be generated for the SMC  (see Section 11.3.1). 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           100 
CONFIDENTIAL  
 After full analysis and final reporting is complete, and upon request and DMID approval, the 
SDCC will provide the participating VTEU site with a summary of results by treatment arm 
and/or subject treatment assignments. In this regard, the participating VTEU site requesting such 
information to share with study subjects must do so in compliance with their respective IRB guidelines. 
15.5. Study Records Retention  
Study documents will be retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical de velopment of the investigational product. These documents will be retained for a 
longer period, however, if required by local regulations. No records will be destroyed without the 
written consent of the sponsor. It is the responsibility of the sponsor to i nform the investigator 
when these documents no longer need to be retained. 
15.6. Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or protocol-
specific MOP requirements. The noncompliance may be either on the pa rt of the subject, the site 
principal investigator, or the site personnel. As a result of deviations, corrective actions are to be developed by the site and implemented promptly. 
These practices are consistent with ICH E6:  
4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3 
5.1 Quality Assurance and Quality Control, Section 5.1.1 
5.20 Noncompliance, Sections 5.20.1, and 5.20.2. 
It is the responsibility of the site principal investigator and personnel to use continuous vigilance 
to identify and re port deviations within five working days of identification of the protocol 
deviation, or within five working days of the scheduled protocol- required activity. All deviations 
must be promptly reported to DMID per the DCC protocol deviation reporting procedures. 
All protocol deviations, as defined above, must be addressed in study subject data collection 
forms. A completed copy of the DMID Protocol Deviation Form must be maintained in the 
Regulatory File, as well as in the subject's chart. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site principal investigator and personnel are responsible for knowing and adhering to their IRB requirements. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           101 
CONFIDENTIAL  
 16 PUBLICATION POLICY  
All investigators funded by the NIH must submit or have submitted for them to the National 
Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an electronic 
version of their final, peer- reviewed manuscripts upon acceptance for publication, to be made 
publicly available no later than 12 months after the official date of publication. The NIH Public Access Policy ensures the public has access to th e published results of NIH funded research. It 
requires investigators to submit final peer- reviewed journal manuscripts that arise from NIH 
funds to the digital archive PubMed Central upon acceptance for publication. Further, the policy stipulates that the se papers must be accessible to the public on PubMed Central no later than 12 
months after publication. 
Refer to:  
NIH Public Access Policy, http://publicaccess.nih.gov/ 
NIH OER Grants and Funding, http://grants.nih.gov/grants/oer.htm  
As of January 2018, al l clinical trials supported by the NIH must be registered on 
ClinicalTrials.gov, no later than 21 days after the enrollment of the first subject. Results of all 
clinical trials supported by the NIH, generally, need to be submitted no later than 12 months 
following the primary completion date. A delay of up to 2 years is available for trials that meet 
certain criteria and have applied for certification of delayed posting. 
As part of the result posting a copy of this protocol (and its amendments) and a copy of the 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this trial the responsible party is DMID which will register the trial and post results.    
The responsible party does not plan to request certification of delayed posting. 
Refer to:  
Public Law 110-85, Section 801, Clinical Trial Databases 42CFR11 
NIH NOT -OD-16-149 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           102 
CONFIDENTIAL  
 17 LITERATURE REFERENCES  
1. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert 
Rev Vaccines. 2014;13(4):521-531. 
2. Weyer J,  Grobbelaar A, Blumberg L. Ebola virus disease: history, epidemiology and 
outbreaks. Curr Infect Dis Rep. 2015;17(5):480. 
3. Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus 
from monkeys imported to USA. Lancet. 1990;335(8688):502-505. 
4. Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses 
from Egyptian fruit bats. PLoS Pathog. 2009;5(7):e1000536. 
5. Towner JS, Pourrut X, Albarino CG, et al. Marburg virus infection detected in a common 
African bat. PLoS One. 2007;2(8):e764. 
6. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus 
disease in the United States. N Engl J Med. 2014;371(25):2402-2409. 
7. Team WHOER, Aylward B, Barboza P, et al. Ebola virus di sease in West Africa --the 
first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481-1495. 
8. Lefebvre A, Fiet C, Belpois -Duchamp C, Tiv M, Astruc K, Aho Glele LS. Case fatality 
rates of Ebola virus diseases: a meta-analysis of World Health Organization data. Med Mal Infect. 2014;44(9):412-416. 
9. Baize S. Towards deep insight into Ebola virus disease. Lancet Infect Dis. 
2015;15(9):991-992. 
10. Martini GA. Marburg virus disease. Postgrad Med J. 1973;49(574):542-546. 
11. Baize S,  Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in 
Guinea. N Engl J Med. 2014;371(15):1418-1425. 
12. Ohimain EI. Recent advances in the development of vaccines for Ebola virus disease. Virus Res. 2016;211:174-185. 
13. Wang Y, Li J, Hu Y, Liang Q, Wei M, Zhu F. Ebola vaccines in clinical trial: The 
promising candidates. Hum Vaccin Immunother. 2017;13(1):153-168. 
14. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implica tions for regulatory approval by the animal rule. Nat Rev 
Microbiol. 2009;7(5):393-400. 
15. Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine 
protection against Ebola virus infection of nonhuman primates. Nat Med. 2011;17(9):1128-1131. 
16. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute 
and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126-1129. 
17. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola v irus infection results in 
substantial immune activation. Proc Natl Acad Sci U S A. 2015;112(15):4719-4724. 
18. Capone S, D'Alise AM, Ammendola V, et al. Development of chimpanzee adenoviruses 
as vaccine vectors: challenges and successes emerging from clini cal trials. Expert Rev 
Vaccines. 2013;12(4):379-393. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           103 
CONFIDENTIAL  
 19. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 
vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 
2010;29(2):304-313. 
20. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee Adenovirus Vector Ebola 
Vaccine. N Engl J Med. 2017;376(10):928-938. 
21. Ewer K, Rampling T, Venkatraman N, et al. A Monovalent Chimpanzee Adenovirus 
Ebola Vaccine Boosted with MVA. N Engl J Med. 2016;374(17):1635-1646. 
22. Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3- EBO- Z Ebola virus vaccine in 
Malian and US adults, and boosting of Malian adults with MVA- BN-Filo: a phase 1, 
single-blind, randomised trial, a phase 1b, open-label and double-blind, dose- escalation 
trial, and a nested, randomised, double-blind, placebo- controlled trial. Lancet Infect Dis. 
2016;16(1):31-42. 
23. Kennedy SB, Bolay F, Kieh M, et al. Phase 2 Placebo- Controlled Trial of Two Vaccines 
to Prevent Ebola in Liberia. N Engl J Med. 2017;377(15):1438-1447. 
24. Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 2007;3(1):e9. 
25. Zahn R, Gillisen G, Roos A, et al. Ad35 and ad26 vaccine vectors induce potent and 
cross-reactive antibody and T- cell responses to multiple filovirus species. PLoS One. 
2012;7(12):e44115. 
26. Parrin o J, McCurdy LH, Larkin BD, et al. Safety, immunogenicity and efficacy of 
modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine. 2007;25(8):1513-1525. 
27. Verheust C, Goossens M, Pauwels K, Breyer D. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine. 
2012;30(16):2623-2632. 
28. Pulendran B. Systems vaccinology: probing humanity's diverse immune systems with 
vaccines. Proc Natl Acad  Sci U S A. 2014;111(34):12300-12306. 
29. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of 
simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl 
Med. 2012;4(115):115ra112. 
30. Peruz zi D, Dharmapuri S, Cirillo A, et al. A novel chimpanzee serotype-based adenoviral 
vector as delivery tool for cancer vaccines. Vaccine. 2009;27(9):1293-1300. 
31. Quinn KM, Da Costa A, Yamamoto A, et al. Comparative analysis of the magnitude, 
quality, phenotype, and protective capacity of simian immunodeficiency virus gag -
specific CD8+ T cells following human -, simian -, and chimpanzee-derived recombinant 
adenoviral vector immunization. J Immunol. 2013;190(6):2720-2735. 
32. Barnes E, Folgori A, Capone S, et al. Novel adenovirus- based vaccines induce broad and 
sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra111. 
33. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on 
chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional 
HCV- specific T cell memory. Sci Transl Med. 2014;6(261):261ra153. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           104 
CONFIDENTIAL  
 34. Suter M, Meisinger- Henschel C, Tzatzaris M, et al. Modified vaccinia Ankara strains 
with identical coding sequences actually represent complex mix tures of viruses that 
determine the biological properties of each strain. Vaccine. 2009;27(52):7442-7450. 
35. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory 
requirements. Nat Methods. 2015;12(4):357-360. 
36. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for 
assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-930. 
37. Aken BL, Achuthan P, Akanni W, et al. Ensembl 2017. Nucleic Acids Res. 
2017;45(D1):D635-D642. 
38. Robinson MD, Oshlack A. A scaling normalization method for differential expression 
analysis of RNA -seq data. Genome Biol. 2010;11(3):R25. 
39. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-140. 
40. Benjamini Y, Hochberg  Y. Controlling the false discovery rate: a practical and powerful 
approach to multiple testing. Journal of the royal statistical society. Series B (Methodological). 1995:289-300. 
41. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in 
hierarchical clustering. Bioinformatics. 2006;22(12):1540-1542. 
42. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. 
Molecular signatures dat abase (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-1740. 
43. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids 
Res. 2000;28(1):27-30. 
44. Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of antibody responses 
derived from a systems biology study of five human vaccines. Nat Immunol. 2014;15(2):195-204. 
45. Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA- seq: 
accounting for selection bias. Genome Biol. 2010;11(2):R14. 
46. Rohart F, Gaut ier B, Singh A, Le Cao KA. mixOmics: An R package for 'omics feature 
selection and multiple data integration. PLoS Comput Biol. 2017;13(11):e1005752. 
47. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33(1):1-22. 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019  
  
 
DMID/NIAID/NIH           105 
CONFIDENTIAL  18 SUPPLEMENTS/APPENDICES 
 
Appendix A: Schedule of Study Procedures and Evaluations  
Appendix B : Estimated Comparative Daily Doses - Inhaled Corticosteroids for Long -Term Asthma 
Control (12 years and older)  
Appendix C: Acceptable Ranges of Screening Laboratory Measurements  
 
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019    
 
DMID/NIAID/NIH           106 
CONFIDENTIAL  
 APPENDIX A : SCHEDULE OF STUDY PROCEDURES AND EVALUATIONS  
Study  Visit (V)  00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 U/S2 ET2 
Study  Day from Vaccine 1  Day <  
-29 to -
1 Day 1  
Vaccine 1  Day 2  Day 3  Day 4  Day 6  Day 8  
+2 Day 9  Day 15  Day 22  Day 29  Day 36  Day 76  
+/- 7 Day 106 
+/-7 Day 182  
+/- 14 - - 
Study Day from Vaccine 2        Day 1  
Vaccine 2  Day 2  Day 8  
+1 Day 15  
+2, - 1 Day 22  
+/- 1 Day 29  
+/- 2   
 - - 
Visit Type  Screen  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Call Call Clinic  Clinic  Clinic  
Obtain Informed Consent∞ X†¬ X¬                
Collect Demographic Information  X                 
Review Eligibility Criteria  X X†¬1     X†¬           
Medical History@ X X†¬1 X X X X X X X X X X X X X X X 
Concomitant Medications  X√ X†¬ X X X X X X X X X X    X X 
Vital Signs (oral temp, pulse, BP)%$ X X†     X†         X X 
Height & Weight  X                 
ECG  X [X] [X] [X] [X] [X] [X]† [X] [X] [X] [X] [X]   [X] [X] [X] 
Physical Examination  X {X}† {X} {X} {X} {X} {X}† {X} {X} {X} {X} {X}   {X} {X} {X} 
Urine or Serum Pregnancy Test ^ X X†     X†           
Urine Dipstick, Opioid testing  X                 
Enrollment/Randomization  X                
Pre-administration reactogenicity assessments   X†     X†           
Study Vaccination   X3     X4           
30-minute evaluation post vax   X     X           
Distribute Memory Aid/Materials   X     X           
Review Memory Aid    X X X X X X X       X X 
Assessment of Adverse Events   X X X X X X X X X X X    X X 
Assessment of SAEs/MAAEs   X X X X X X X X X X X X X X X X 
                  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019    
 
DMID/NIAID/NIH           107 
CONFIDENTIAL  
  
                    
Study  Visit (V)  00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 U/S2 ET2 
Study  Day from Vaccine 1  Day <  
-29 to -
1 Day 1  
Vaccine 1  Day 2  Day 3  Day 4  Day 6  Day 8  
+2 Day 9  Day 15  Day 22  Day 29  Day 36  Day 76  
+/- 7 Day 106 
+/-7 Day 182  
+/- 14 - - 
Study Day from Vaccine 2        Day 1  
Vaccine 2  Day 2  Day 8  
+1 Day 15  
+2/ - 1 Day 22  
+/- 1 Day 29  
+/- 2    
 - - 
Visit Type  Screen  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Clinic  Call Call Clinic  Clinic  Clinic  
Laboratory Assessments5 
Screening Labs~  14.2= & 
>                 
 HLA typing for Class 1 (A, B, C locus)   6†                
Clinical Safety Evaluations *  6.5†     6.5†  6.5  6.5 6.5    6.5 6.5 
Humoral response – ELISA   
10†     
10†  
10 10 10 10     
10 Humoral response - ADCC            
Humoral Response, EBOV GP Neut Antibody             
  
EBOV GP T cell responses   
24†     
24†  
24 24  
24      
ChAd3 vector T cell responses              
 Plasmablasts   24†     24†  24         
Cd8 Tetramer Staining   8†     8†  8        8 
Activation Marker Analysis               
Exploratory cytokine/chemokine  
 
    5† 5 5 5 5 5† 5 5         
 Transcriptomics/Gene Expression PBMCs 8)   16† 16 16 16 16 16† 16 16         
Yeast Display             16      
Future Use Collection   8†     8†  8 8  8   42   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019    
 
DMID/NIAID/NIH           108 
CONFIDENTIAL  
 ∞ Prior to study procedures.  
†  Prior to study vaccination.  
¬  Review/confirm information or activity in subjects previously consented and screened. 
1  Review results of clinical screening laboratory evaluations.  
@ Complete medical history will be obtained by interview of subjects at the screening visit and will be updated on Day 1 prior to the first study vaccination and interim medical history will be obtained 
by interview of subjects at follow- up visits after the first study vaccination.  
% Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
$ Vital signs assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
√ All current medications and medications taken within 60 days prior to signing the informed consent form.  
^ Will be performed on all women of childbearing potential at screening (serum) and within 24 hours prior to study vaccination (urine) and results must be negative and known prior to each study 
vaccination. 
~ Screening laboratories include: WBC, Hgb, HgbA1C, platelets, ANC, sodium, potassium, BUN  (only assessed if creatinine is above the normal range) , creatinine, albumin, total protein, Alanine 
aminotransferase (ALT), hepatitis B surface antigen, hepatitis C antibody, HIV types 1 and 2, Prothrombin time (PT),  partial thromboplastin time (PTT).  
= All clinical screening laboratory evaluations are to be performed at screening and the values are to be reviewed prior to the first study vaccination on Day 1; no additional blood draws for this are 
required on Day 1.   
& Retesting of values that lead to exclusion is allowed once using an unscheduled visit during the screening period, provided there is an alternative explanation for the out of range value.  
> If the initial laboratory screening occurred more than 28 days before baseline (Day 1) but the subject was unable to be vaccinated within the 28 -day window (e.g., due to meeting Exclusion Criteria or 
for other reasons), the subject must have laboratories repeated.  
{ } Targeted physical examination if indicated based on review of interim medical history.  
[ ]  ECG will be completed if clinically indicated based on signs/symptoms per the Investigator’s judgement 
* Safety laboratories include: WBC, Hgb, platelets, ANC, sodium, potassium, BUN  (only assessed if creatinine is above the normal range) , creatinine, Alanine aminotransferase (ALT).  
2 Refer to protocol for specific procedures and time points  for ET or U/S visit.  
3 Single dose of 2 x 1011 vp ChAd3- EBO -Z. 
4 Single dose of Booster Vaccination (Group 1: placebo, Group 2: 2 x 1011 vp  ChAd3- EBO -Z., Group 3:  1 x 108 IU MVA -BN®-Filo ). 
5 Volume of blood listed is in ml  
  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019    
 
DMID/NIAID/NIH           109 
CONFIDENTIAL  
 APPENDIX B: ESTIMATED COMPARATIVE DAILY DOSES - INHALED 
CORTICOSTEROIDS FOR LONG-TERM ASTHMA CONTROL (12 YEARS 
AND OLDER)  
Medication – Daily Dose  Low  Medium  High  
Beclomethasone MDI  80 to 240 micrograms  more than 240 to 480 micrograms  more than 480 micrograms  
40 micrograms per puff  1 to 3 puffs twice a day 4 to 6 puffs twice a day    
80 micrograms per puff  1 puff a.m.,  
2 puffs p.m.  2 to 3 puffs twice a day 4 or more puffs twice a day  
Budesonide DPI  180 to 540 micrograms  more than 540 to 1,080 micrograms  more than 1,080 micrograms  
90 micrograms per inhalation  1 to 3 inhalations twice a day      
180 micrograms per inhalation  1 inhalation a.m.,  
2 inhalations p.m.  2 to 3 inhalations twice a day  4 or more inhalations twice a day  
Budesonide Nebules  not applicable  not applicable  not applica ble 
0.25 mg  not applicable  not applicable  not applicable  
0.5 mg  not applicable  not applicable  not applicable  
1.0 mg  not applicable  not applicable  not applicable  
Ciclesonide MDI  160 to 320 micrograms  more than 320 to 640 micrograms  more than 640 micrograms  
80 micrograms per puff  1 to 2 puffs twice a day  3 to 4 puffs twice a day   
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019    
 
DMID/NIAID/NIH           110 
CONFIDENTIAL  
 160 micrograms per puff    2 puffs twice a day  3 or more puffs twice a day  
Flunisolide MDI  320 micrograms  more than 320 to 640 micrograms  more than 640 micrograms  
80 micrograms per puff  2 puffs twice a day  3 to 4 puffs twice a day 5 puffs or more twice a day  
Fluticasone MDI  88 to 264 micrograms  more than 264 to 440 micrograms  more than 440 micrograms  
44 micrograms per puff  1 to 3 puffs twice a day      
110 micrograms per puff    2 puffs twice a day  3 puffs twice a day  
220 micrograms per puff    1 puff twice a day  2 or more puffs twice a day  
Fluticasone DPI  100 to 300 micrograms  more than 300 to 500 micrograms  more than 500 micrograms  
50 micrograms per inhalation  1 to 3 inhalations twice a day      
100 micrograms per inhalation    2 inhalations twice a day  3 or more inhalations twice a day  
250 micrograms per inhalation    1 inhalations twice a day  2 or more inhalations twice a day  
Mometasone DPI  110 to 220 micrograms  more than 220 to 440 micrograms  more than 440 micrograms  
110 micrograms per inhalation  1 to 2 inhalations p.m.  3 to 4 inhalations p.m. or 2 inhalations twice a day  3 or more inhalations twice a day  
220 micrograms per inhalation  1 inhalation p.m.  1 inhalation twice a day or 2 inhalations p.m.  3 or more inhalations divided in two doses  
 
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019    
 
DMID/NIAID/NIH           111 
CONFIDENTIAL  
 APPENDIX C : ACCEPTABLE RANGES OF SCREENING LABORATORY 
MEASUREMENTS 
Lab Test Name  Clinical 
Laborator yRefer
ence Range  Study Eligibility 
Acceptable 
Lower Limit Study Eligibility 
Acceptable  
Upper Limit Lab Unit 
Hemoglobin, male  13.30  - 17.70 13.30 17.70 g/dL  
Hemoglobin, female  11.70  - 15.70 11.70 15.70 g/dL  
White blood cell count (WBC)  (18 to 
<21 years)  4.5 – 13.0 3.6  13.0 K/mcL  
White blood cell count(WBC) (≥21 
years)  4.5 – 11.0 3.6 11.0 K/mcL  
Absolute Neutrophil count * 1.80 – 7.70 1.80 7.70 K/mcL  
Platelet count  135 - 466 135 466 K/mcL  
PT 9.60 – 11.30 9.60 11.30 seconds  
PTT 25.00 – 34.5 25.00 34.50 seconds  
Sodium  136.0 – 145.0 136.0 145.0  mmol/L  
Potassium  3.5 – 5.1 3.5 5.1 mmol/L  
Blood urea nitrogen (BUN)  † 9.0 – 23.00 <9.0† 23.00 mg/dL  
Serum creatinine †, male  0.60 – 1.10 <0.60† 1.3 mg/dL  
DMID #14 -0092 Ebola         Version 6.0 _30 January 2019    
 
DMID/NIAID/NIH           112 
CONFIDENTIAL  
 Serum creatinine †, female  0.50 – 0.80 <0.50† 1.2 mg/dL  
Total protein  5.70 – 8.20 5.70 8.20 g/dL  
Albumin  3.40 - 5.00 3.40 5.00 g/dL  
Alanine transferase † (ALT) ≤ 49 n/a 49 unit/L 
Hepatitis B surface antigen  Negative  Negative  Negative   n/a 
Hepatitis C antibodies  Negative  Negative  Negative   n/a 
HIV -  1/2 Ab Negative  Negative  Negative   n/a 
Serum hCG (females only) Negative  Negative  Negative  n/a 
*  ANC for subjects that are of African American and Middle Eastern descent may have values as low as 0.8 K/mcL . Subjects of this descent must have an ANC ≥ 
0.8 K/mc L to be eligible to participate in the study if all other study criteria are met.   
†  Values of  serum creatin ine and blood urea nitrogen (BUN) below the lower limit of normal (LLN) are acceptable for study enrollment . 
 
 
 